(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 October 2012 (11.10.2012)

(10) International Publication Number
WO 2012/137147 Al

(51) International Patent Classification:
C07K 14/37 (2006.01) *CUD 3/386* (2006.01)
CUD 3/38 (2006.01) *C12N 9/20* (2006.01)

(21) International Application Number:
PCT/IB20 12/05 1660

(22) International Filing Date:
4 April 2012 (04.04.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN201 1/000614 8 April 201 1 (08.04.201 1) CN
61/561,044 17 November 201 1 (17. 11.201 1) US

(71) Applicant *(for all designated States except US):* **DANISCO US, INC.** [US/US]; 925 Page Mill Road, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only):* **SHIPOVSKOV, Stepan** [RU/DK]; Kystparkvej 18, DK-8250 Ega (DK). **JENSEN, Lene Bojsen** [DK/DK]; Provsteparkvej 26, DK-8270 H0jbjerg (DK). **QIAN, Zhen** [CN/CN]; Room 502, No 19, Lane 47 Yanzhong Road, Shanghai 200125 (CN).

(74) Agent: **DUNCAN, Garreth;** D Young & Co LLP, 120 Holborn, London EC1N 2DY (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available):* AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available):* ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/137147 A1

(54) Title: COMPOSITIONS

(57) Abstract: A composition comprising: (a) a lipolytic enzyme; (b) a hydrophobin, as defined herein; and optionally (c) a detergent; is provided. The composition is usefui as a cleaning composition for removing lipid-based stains from surfaces.

COMPOSITIONS

Field of the invention

5 This invention relates to a composition, particularly although not exclusively for use as a detergent. The invention also relates to methods of cieaning surfaces and items, such as clothing items and tableware items, using the composition.

Background to the Invention

10

As described in Wosten, *Annu. Rev. Microbiol.* 2001, 55, 625-646, hydrophobins are proteins generally of fungal origin that play a broad range of roles in the growth and development of filamentous fungi. For example, they are involved in the formation of aerial structures and in the attachment of hyphae to hydrophobic surfaces.

15

The mechanisms by which hydrophobins perform their function are based around their property to self-assemble at hydrophobic-hydrophi!ic interfaces (particularly air-water interfaces) into an amphipathic film.

20 Typically, hydrophobins are divided into Classes I and II. As described in more detail herein, the assembled amphipathic films of Class II hydrophobins are capable of redissoiving in a range of solvents (particularly although not exclusively an aqueous ethanol) at room temperature. In contrast, the assembled amphipathic films of Class I hydrophobins are much less soluble, redissoiving only in strong acids such as
25 trifluoroacetic acid or formic acid.

Detergent compositions containing hydrophobins are known in the art. For example, US 2009/0101 167 (corresponding to WO 2007/014897) describes the use of hydrophobins, particularly fusion hydrophobins, for washing textiles and washing
30 compositions containing them.

There remains a need in the art for detergent compositions containing surfactants capable of being used in smaller quantities and thereby minimising impact on the environment.

35

Summary of the Invention

According to one aspect of the invention, there is provided a composition comprising:
(a) a lipolytic enzyme; and
5 (b) a hydrophobin, as defined herein.

According to another aspect of the invention, there is provided a composition comprising:
(a) a lipolytic enzyme;
10 (b) a hydrophobin, as defined herein; and
(c) a detergent.

According to one aspect of the invention, there is provided a composition comprising:
(a) a GX lipolytic enzyme, wherein G is glycine and X is an oxyanion hole-forming
15 amino acid residue, wherein the GX lipolytic enzyme belongs to an alpha/beta hydrolase superfamily selected from the group consisting of abH23, abH25, and abH15; and
(b) a hydrophobin, as defined herein.

20 According to another aspect of the invention, there is provided a composition comprising:
(a) a GX lipolytic enzyme, wherein G is glycine and X is an oxyanion hole-forming amino acid residue;
(b) a hydrophobin, as defined herein; and
25 (c) a detergent.

According to a yet further aspect of the invention, there is provided a method of removing a lipid-based stain from a surface by contacting the surface with a composition as defined herein.

30

According to a still further aspect of the invention, there is provided the use of a composition as defined herein to reduce or remove lipid stains from a surface.

According to a further aspect of the invention, there is provided a method of cleaning
35 a surface, comprising contacting the surface with a composition as defined herein.

According to a further aspect of the invention, there is provided a method of cleaning an item, in particular a clothing item or a tableware item, comprising contacting the item **with** a composition as defined herein.

5 Advantages

It has surprisingly been found **that** the combination of hydrophobin, lipolytic enzyme and, optionally, detergent is capable of removing oily soils from surfaces, such as textile, clothing or tableware surfaces: it is generally problematic to remove such soils
10 using existing commercial detergents. This effect confers the potential for using the combination in washing compositions.

In particular, it has surprisingly been found that the combination of hydrophobin and GX lipolytic enzyme selected from the abH superfamilies referred to above exhibits a
15 greatly improved cleaning effect than would be expected from an additive effect of either of these proteins when used alone. These properties confer the potential for using the combination as a replacement for detergent in washing compositions, thereby minimising the environmental impact of such compositions.

20 It has also surprisingly been found that the combination of hydrophobin, GX lipolytic enzyme and detergent exhibits a greatly improved cleaning effect than would be expected from an additive effect of any of these three components when used alone. These properties confer the potential for using the combination to minimise the amount of detergent required in washing compositions, thereby minimising the
25 environmental impact of such compositions.

Brief Description of the Drawings

Fig. 1a shows the % change in Stain Removal index (SRI) as a function of the
30 detergent concentration at various specified hydrophobin concentrations in the presence of heat-inactivated liquid detergent ARIEL™ Color, but in the absence of a lipolytic enzyme;

Fig. 1b shows the % change in SRI as **a** function of the hydrophobin concentration at various specified detergent concentrations in the presence of heat-inactivated liquid
35 detergent ARIEL™ Color, but in the absence of a lipolytic enzyme;

Fig. 1c shows the % change in SRI as a function of the detergent concentration at various specified hydrophobin concentrations in the presence of heat-inactivated powder detergent ARIEL™ Color, but in the absence of a lipolytic enzyme;

Fig. 2a shows the % change in SRI as a function of the detergent concentration at various specified hydrophobin concentrations in the presence of the lipolytic enzyme LIPEX™ and the heat-inactivated liquid detergent ARIEL™ Color;

Fig. 2b shows the % change in SRI as a function of the hydrophobin concentration at various specified detergent concentrations in the presence of the lipolytic enzyme LIPEX™ and the heat-inactivated liquid detergent ARIEL™ Color;

Fig. 2c shows the % change in SRI as a function of the detergent concentration at various specified hydrophobin concentrations in the presence of the lipolytic enzyme LIPEX™ and the heat-inactivated powder detergent ARIEL™ Color;

Fig. 2d shows the % change in SRI as a function of the hydrophobin concentration at various specified detergent concentrations in the presence of the lipolytic enzyme LIPEX™ and the heat-inactivated powder detergent ARIEL™ Color;

Fig. 2e shows the % change in SRI as a function of the hydrophobin concentration in the presence of the lipolytic enzyme LIPEX™ but in the absence of detergent;

Fig. 3a shows the % change in SRI as a function of the detergent concentration at various specified hydrophobin concentrations in the presence of the lipolytic enzyme LIPOMAX™ and the heat-inactivated liquid detergent ARIEL™ Color;

Fig. 3b shows the % change in SRI as a function of the hydrophobin concentration at various specified detergent concentrations in the presence of the lipolytic enzyme LIPOMAX™ and the heat-inactivated liquid detergent ARIEL™ Color;

Fig. 3c shows the % change in SRI as a function of the detergent concentration at various specified hydrophobin concentrations in the presence of the lipolytic enzyme LIPOMAX™ and the heat-inactivated powder detergent ARIEL™ Color;

Fig. 3d shows the % change in SRI as a function of the hydrophobin concentration at various specified detergent concentrations in the presence of the lipolytic enzyme LIPOMAX™ and the heat-inactivated powder detergent ARIEL™ Color;

Fig. 3e shows the % change in SRI as a function of the hydrophobin concentration in the presence of the lipolytic enzyme LIPOMAX™ but in the absence of detergent;

Fig. 4a shows the % change in SRI as a function of the detergent concentration at various specified hydrophobin concentrations in the presence of the lipolytic enzyme SprLip2 and the heat-inactivated liquid detergent ARIEL™ Color;

Fig. 4b shows the % change in SRI as a function of the hydrophobin concentration at various specified detergent concentrations in the presence of the lipolytic enzyme SprLip2 and the heat-inactivated liquid detergent ARIEL™ Color;

Fig. 4c shows the % change in SRI as a function of the detergent concentration at various specified hydrophobin concentrations in the presence of the lipolytic enzyme SprUp2 and the heat-inactivated powder detergent ARIEL™ Color;

Fig. 4d shows the % change in SRI as a function of the hydrophobin concentration at
5 various specified detergent concentrations in the presence of the lipolytic enzyme SprLip2 and the heat-inactivated powder detergent ARIEL™ Color;

Fig. 4e shows the % change in SRi as a function of the hydrophobin concentration in the presence of the lipolytic enzyme Sprl_ip2 but in the absence of detergent;

Fig. 5a shows the % change in SRi as a function of the detergent concentration at
10 various specified hydrophobin concentrations in the presence of the lipolytic enzyme TfuLip2 and the heat-inactivated liquid detergent ARIEL™ Color;

Fig. 5b shows the % change in SR! as a function of the hydrophobin concentration at various specified detergent concentrations in the presence of the lipolytic enzyme TfuLip2 and the heat-inactivated liquid detergent ARIEL™ Color;

15 Fig. 5c shows the % change in SRI as a function of the detergent concentration at various specified hydrophobin concentrations in the presence of the lipolytic enzyme TfuLip2 and the heat-inactivated powder detergent ARIEL™ Color;

Fig. 5d shows the % change in SRI as a function of the hydrophobin concentration at various specified detergent concentrations in the presence of the lipolytic enzyme
20 TfuLip2 and the heat-inactivated powder detergent ARIEL™ Color;

Fig. 5e shows the % change in SRI as a function of the hydrophobin concentration in the presence of the lipolytic enzyme TfuLip2 but in the absence of detergent;

Fig. 6 shows SEQ ID NO: 1, the DNA sequence encoding the hydrophobin *Trichoderma reesei* HFBII (Y1 1894.1);

25 Fig. 7 shows SEQ ID NO: 2, the amino acid sequence of the hydrophobin *Trichoderma reesei* HFBII (P79073.1);

Fig. 8 shows SEO ID NO: 3, the DNA sequence encoding the hydrophobin *Trichoderma reesei* HFBI (Z68124.1);

Fig. 9 shows SEQ ID NO: 4, the amino acid sequence of the hydrophobin
30 *Trichoderma reesei* HFBI (P52754. 1);

Fig. 10 shows SEQ ID NO: 5, the DNA sequence encoding the hydrophobin *Schizophyllum commune* SC3 (M32329.1);

Fig. 11 shows SEQ ID NO: 6, the amino acid sequence of the hydrophobin *Schizophyllum commune* SC3 (AAA96324.1);

35 Fig. 12 shows SEQ ID NO: 7, the DNA sequence encoding the hydrophobin *Neurospora crassa* EAS (X67339.1);

Fig. 13 shows SEQ ID NO: 8, the amino acid sequence of the hydrophobin *Neurospora crassa* EAS (AAB24462.1);

Fig. 14 shows SEQ ID NO: 9, *Talaromyces thermophilus* TT1 (the DNA sequence encoding the precursor TT1 hydrophobin, SEQ ID NO: 4 of US 7241734);

5 Fig. 15 shows SEQ ID NO: 10, *Talaromyces thermophilus* TT1 (the amino acid sequence of the precursor TT1 hydrophobin, SEQ ID NO: 3 of US 7241734);

Fig. 16 shows SEQ ID NO: 11 the mature amino acid sequence of LIPEX™;

Fig. 17 shows SEQ ID NO: 12 the full amino acid sequence for Sprl_ip2 (*Strepiomyces pristinaespiralis* ATCC 25486 Uniprot B5H9Q8, NCBI:

10 ZP_06912654.1) with the signal sequence shown in bold;

Fig. 18 shows SEQ ID NO: 13 the mature amino acid sequence of the *Fusarium heterosporum* phosphoiipase (disclosed in WO 2005/087918 and available from Danisco A/S as GRINDAMYL POWERBAKE 4100™);

Fig. 19 shows SEQ ID NO: 29 the full amino acid sequence of Lipase 3 disclosed in

15 WO 98/45453, residues 1 to 270 comprise the mature sequence referred to herein as SEQ ID NO: 14;

Fig. 19a shows SEQ ID NO: 14 the mature amino acid sequence of Lipase 3;

Fig. 20 shows SEQ ID NO: 15 the mature amino acid sequence of LIPOMAX™;

Fig. 21 shows SEQ ID NO: 16 the mature amino acid sequence of TfuLip2;

20 Fig. 22 shows SEQ ID NO: 17 the mature amino acid sequence of SprLip2;

Fig. 23 shows SEQ ID NO: 18 the full amino acid sequence of LIPEX, including the signal sequence (amino acid residues 1 to 17), propeptide (amino acid residues 18 to 22) and mature sequence (amino acid residues 23 to 291 - shown in Fig. 16 as SEQ ID NO: 11);

25 Fig. 24 shows SEQ ID NO: 19 the full amino acid sequence of LIPOMAX, including the signal sequence (amino acid residues 1 to 24) and mature sequence (amino acid residues 25 to 313 - shown in Fig. 20 as SEQ ID NO: 15);

Fig. 25 shows SEQ ID NO: 20 the full amino acid sequence of TfuLip2, including the signal sequence (amino acid residues 1 to 40) and mature sequence (amino acid

30 residues 41 to 301 - shown in Fig. 21 as SEQ ID NO: 16);

Fig. 26 shows a protein preprosequence SEQ ID NO: 21 of a lipolytic enzyme from *Fusarium heterosporum* CBS 782.83 (wild type) disclosed in WO 2005/087918 - the preprosequence undergoes translational modification such that the mature form of the enzyme preferably comprises the enzyme shown in Fig. 18 as SEQ ID NO: 13; in

35 some host organisms the protein may be N-terminally processed such that a number of additional amino acids are added to the N or C terminus;

Fig. 27 shows SEQ !D NO: 22 the nucleotide sequence of the synthesized *SprUp2* gene;

Fig. 28 shows SEQ !D NO: 23 the nucleotide sequence of the SprLip2 gene from expression piasmid pZQ205 (celA signal sequence is underlined);

Fig. 29 shows SEQ !*D* NO: 24 the amino acid sequence of Sprl_ip2 produced from p!asmid pZQ205 (signal sequence is underlined);

Fig. 30 shows the piasmid map of pZQ205 expression vector;

Fig. 31 shows pNB hydrolysis by Sprl_ip2;

Fig. 32 shows pNPP hydrolysis by SprLip2;

Fig. 33 shows trioctanoate hydrolysis in the absence of detergent by SprLip2;

Fig. 34 shows trioctanoate hydrolysis in the presence of detergent by SprLip2;

Fig. 35 shows the performance of SprLip2 in the presence and absence of detergent;

Fig. 36 shows SEQ !D NO: 25, the amino acid sequence of a lipase from *Geobacillus stearotherrnophilus* strain T1 (GeoT1) which is available on the NCB! database as accession number JC8061 (signal sequence is underlined);

Fig. 37 shows SEQ !D NO: 26 the amino acid sequence of the BCE-GeoT1 fusion protein which is a fusion of SEQ !D NO: 25 and the carboxy-terminus of the catalytic domain of a bacterial cellulase;

Fig. 38 shows SEQ !D NO: 27 the amino acid sequence of a lipase from *Bacillus subtilis* 168 (LipA) which is available as GENBANK Accession No. P37957 (signal sequence is underlined);

Fig. 39 shows SEQ ID NO: 28 the amino acid sequence of the BCE-LipA fusion protein which is a fusion of SEQ !D NO: 27 and the carboxy-terminus of the catalytic domain of a bacterial cellulase; and

Fig. 40 shows SEQ !D NO: 30 the nucieotide sequence of the Nsil-Mlul-Hpal enzyme restriction sites before the BamHI site.

Detailed Description of Preferred Embodiments

HYDROPHOBINS

In this specification the term "hydrophobin" is defined as meaning a polypeptide capable of self-assembly at a hydrophilic / hydrophobic interface, and having the general formula (I):

$$(Y_1)_n\text{-}B_1\text{-}(X_1)_a\text{-}B_2\text{-}(X_2)_b\text{-}B_3\text{-}(X_3)_c\text{-}B_4\text{-}(X_4)_d\text{-}B_5\text{-}(X_5)_e\text{-}B_6\text{-}(X_6)_f\text{-}B_7\text{-}(X_7)_g\text{-}B_8\text{-}(Y_2)_m \quad (1)$$

wherein:

m and n are independently 0 to 2000;

B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu, Ala, Pro, Ser, Thr, Met or Gly, at least 6 of the residues B_1 through B_8 being Cys;

5 X_1, X_2, X_3, X_4, X_5, X_6, X_7, Y_1 and Y_2 independently represent any amino acid;

a is 1 to 50;

b is 0 to 5;

c is 1 to 100;

d is 1 to 100;

10 e is 1 to 50;

f is 0 to 5; and

g is 1 to 100.

Suitably, the hydrophobin has a sequence of between 40 and 120 amino acids in the
15 hydrophobin core. More preferably, the hydrophobin has a sequence of between 45 and 100 amino acids in the hydrophobin core. In one embodiment, the hydrophobin has a sequence of between 50 and 90, preferably 50 to 75, and more preferably 55 to 65 amino acids in the hydrophobin core. In this specification the term "the hydrophobin core" means the *sequence beginning with the* residue B_1 and
20 terminating with the residue B_8.

In the formula (I), at least 6, preferably at least 7, and most preferably all 8 of the residues B_1 through B_8 are Cys.

25 In the formula (I), in one embodiment m is suitably 0 to 500, preferably 0 to 200, more preferably 0 to 100, still more preferably 0 to 20, yet more preferably 0 to 10, still more preferably 0 to 5, and most preferably 0.

In the formula (I), in one embodiment n is suitably 0 to 500, preferably 0 to 200, more
30 preferably 0 to 100, still more preferably 0 to 20, yet more preferably 0 to 10, and most preferably 0 to 3.

In the formula (I), a is preferably 3 to 25, more preferably 5 to 15. In one embodiment, a is 5 to 9.

35

In the formula (I), b is preferably 0 to 2, more preferably 0.

in the formula 0), c is preferably 5 to 50, more preferabiy 5 to 40. In one embodiment, c is i 1 to 39.

in the formula (I), d is preferabiy 2 to 35, more preferabiy 4 to 23. In one embodiment, d is 8 to 23.

in the formula (I), e is preferabiy 2 to 15, more preferabiy 5 to 12. In one embodiment, e is 5 to 9.

In the formula (I), f is preferabiy 0 to 2, more preferabiy 0.

in the formula (i), g is preferably 3 to 35, more preferably 6 to 21. in one embodiment, g is 6 to 18.

Preferably, the hydrophobins used in the present invention have the general formula (II):



wherein:

m and n are independently 0 to 20;

B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu, Ala, Pro, Ser, Thr, Met or Gly, at least 7 of the residues B_1 through B_8 being Cys;

a is 3 to 25;

b is 0 to 2;

c is 5 to 50;

d is 2 to 35;

e is 2 to 15;

f is 0 to 2; and

g is 3 to 35.

In the formula (II), at (east 7, and preferably all 8 of the residues B_1 through B_8 are Cys.

More preferably, the hydrophobins used in the present invention have the general formula (111):



wherein:

m and n are independently 0 to 20;

B,, B_2, B?, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu, Ala, Pro, Ser, Thr, Met or Gly, at least 7 of the residues B_1 through B_8 being Cys;

a is 5 to 15;

c is 5 to 40;

d is 4 to 23;

e is 5 to 12; and

g is 6 to 21.

!n the formula (ill), at least 7, and preferably 8 of the residues B_1 through B_8 are Cys.

In the formulae (i), (IS) and (III), when 6 or 7 of the residues B_1 through B_8 are Cys, it is preferred that the residues B_3 through B_7 are Cys.

In the formulae (I), (II) and (III), when 7 of the residues B, through B_8 are Cys, it is preferred that: (a) B_1 and B_3 through B_8 are Cys and B_2 is other than Cys; (b) B_1 through B_7 are Cys and B_8 is other than Cys, (c) B-, is other than Cys and B_2 through B_8 are Cys. When 7 of the residues B_1 through B_8 are Cys, it is preferred that the other residue is Ser, Pro or Leu. In one embodiment, B_1 and B_3 through B_8 are Cys and B_2 is Ser. In another embodiment, B_1 through B_7 are Cys and B_8 is Leu. In a further embodiment, B_1 is Pro and B_2 through B_8 are Cys.

The cysteine residues of the hydrophobins used in the present invention may be present in reduced form or form disulfide (-S-S-) bridges with one another in any possible combination. In one particularly preferred embodiment, when all 8 of the residues B_1 through B_8 are Cys, disulfide bridges may be formed between one or more (preferably at least 2, more preferably at least 3, most preferably all 4) of the following pairs of cysteine residues: B_1 and B_6; B_2 and B_5; B_3 and B_4; B_7 and B_8. In one alternative preferred embodiment, when all 8 of the residues B_1 through B_8 are Cys, disulfide bridges may be formed between one or more (preferably at least 2, more preferably at least 3, most preferably all 4) of the following pairs of cysteine residues: B_1 and B_2; B_3 and B_4; B_5 and B_6; B_7 and B_8.

Examples of specific hydrophobic useful in the present invention include those described and exemplified in the following publications: Under ef a/., *FEMS Microbiology Rev.* 2005, *29,* 877-896; Kubicek *et al., BMC Evolutionary Biology,* 2008, *8,* 4; Sunde *ef al., Micron,* 2008, 39, 773-784; Wessels, *Adv. Micr. Physiol.*
5 1997, *33,* 1-45; Wosten, *Annu. Rev. Microbiol.* 2001, *55,* 625-646; Hektor and Scholtmeijer, *Curr. Opin. Biotech.* 2005, *16,* 434-439; Szilvay *et al., Biochemistry,* 2007, *46,* 2345-2354; Kisko *et al. Langmuir,* 2009, *25,* 1612-1619; B!ijdenstein, *Soft Matter,* 2010, *6,* 1799-1808; Wosten *et al., EMBO J.* 1994, *13,* 5848-5854; Hakanpaa et a/., *J. Biol. Chem.,* 2004, 279, 534-539; Wang et a/.; *Protein* Sc/., 2004, *13,* 810-
10 821 ; De Vocht et a/., *Biophys. J.* 1998, 74, 2059-2068; Askolin ef a/., *Biomacromolecules* 2006, 7, 1295-1301 ; Cox et a/.; *Langmuir,* 2007, 23, 7995-8002; Linder ef a/., *Biomacromolecules* 2001 , 2, 511-517; Kallio ef a/. *J Blo/. Chem.,* 2007, 282, 28733-28739; Scholtmeijer ef a/., *Appl. Microbiol. Biotechnol.,* 2001, 56, 1-8; Lumsdon *et al., Colloids & Surfaces B: Biosnterfaces,* 2005, *44,* 172-178; Palomo ef
15 a/., *Biomacromolecules* 2003, 4, 204-210; Kirkland and Keyhani, J. /nd. *Microbiol. Biotechnol.,* July 17 2010 (e-publication); Stubner ef a/., /nt. J. Foot/ *Microbiol.,* 30 June 2010 (e-pubiication); Laaksonen *et al. Langmuir,* 2009, 25, 5185-5192; Kwan ef a/. J. *Mol. Biol.* 2008, 382, 708-720; Yu *et al. Microbiology,* 2008, 154, 1677-1685; Lahtinen *etal. Protein Expr. Purif.,* 2008, *59,* 18-24; Szilvay *etal., FEBS Lett,* 2007,
20 *5811,* 2721-2726; Hakanpaa ef *al., Acta Crystallogr. D. Biol. Crystallogr.* 2006, *62,* 356-367; Scholtmeijer ef a/., *App/. Environ. Microbiol.,* 2002, 68, 1367-1373; Yang et al, *BMC Bioinformatics,* 2006, 7 Supp. 4, S16; WO 01/57066; WO 01/57528; WO 2006/082253; WO 2006/103225; WO 2006/103230; WO 2007/014897; WO 2007/087967; WO 2007/087968; WO 2007/030966; WO 2008/019965;
25 WO 2008/107439; WO 2008/1 10456; WO 2008/1 16715; WO 2008/120310; WO 2009/050000; US 2006/0228484; and EP 2042 156A; the contents of which are incorporated herein by reference.

In one embodiment, the hydrophobin is a polypeptide selected from SEO ID NOs: 2,
30 4, 6 8 or 10, or a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 99% sequence identity in the hydrophobin core to any thereof and retaining the above-described self-assembly property of hydrophobins.

35

Sources of h'ydrophobins

In one embodiment, the hydrophobin is obtained or obtainable from a microorganism. The microorganism may preferably be a bacteria or a fungus, more preferably a
5 fungus. In a preferred embodiment, the hydrophobin is obtained or obtainable from a filamentous fungus.

In one embodiment, the hydrophobin is obtained or obtainable from fungi of the phyla Basidiomycota or Ascornycota.

10

In one embodiment, the hydrophobin is obtained or obtainable from fungi of the genera *Cladosporium* (particularly *C. fulvum* or *C. herbarum), Ophistoma* (particularly *O. ulmi), Cryphonectria* (particularly *C. parasitica), Trichoderma* (particularly *T. harzianum, T. longibrichiatum, T. asperellum, T. Koningiopsis, T. aggressivum, T.*
15 *stromaticum* or *T. reesei), Gibberella* (particularly *G. moniliformis), Neurospora* (particularly *N. crassa), Maganaporthe* (particularly *M. grisea), Hypocrea* (particularly *H.jecorina, H. atroviridis, H. virens* or *H lixii), Xanthoria* (particularly *X. ectanoides* and *X. parietina), Emericella* (particularly *E. nidulans), Aspergillus* (particularly *A. fumigatus, A. oryzae), Paracoccioides* (particularly *P. brasiliensis), Metarhizium*
20 (particularly *M. anisoplaie), Pleurotus* (particularly P. *ostreatus), Coprinus* (particularly *C. cinereus), Dicotyonema* (particularly *D. glabratum), Flammulina* (particularly *F. velutipes), Schizophyllum* (particularly S. *commune), Agaricus* (particularly *A. bisporus), Pisolithus* (particularly P. *tinctorius), Tricholoma* (particularly *T. terreum), Pholioka* (particularly P. *nameko), Talaromyces* (particularly
25 *T. thermophilus)* or *Agrocybe* (particularly *A. aegerita).*

Assays

One property of the hydrophobins used in the present invention is the self-assembly
30 property of the hydrophobins at a hydrophilic / hydrophobic interface.

In accordance with the definition of the present invention, self-assembly can be detected by adsorbing the protein to polytetrafluoroethylene (TEFLON®) and using Circular Dichroism (CD) to establish the change in secondary structure exemplified
35 by the occurrence of motifs in the CD spectrum corresponding to a newly formeda-helix) (De Vocht ef *a/., Biophys. J.* 1998, *74,* 2059-2068). A full procedure for

carrying out the CD spectral analysis can be found in Askolin *et a!. Biomacromo!ecules,* 2006, 7, 1295-1301 .

in one embodiment, the hydrophobins used in the present invention are
5 characterised by their effect on the surface properties at an interface, particularly although not exclusively at an air/water interface. The surface property may be surface tension (especially equilibrium surface tension) or surface shear rheology, particularly the surface shear elasticity (storage modulus).

10 In one embodiment, the hydrophobin may cause the equilibrium surface tension at a water/air interface to reduce to below 45 mN/m, preferably below 40 mN/m, and more preferably below 35 mN/m. In contrast, the surface tension of pure water is 72 mN/m room temperature. Typically, such a reduction in the equilibrium surface tension at a water/air interface may be achieved using a hydrophobin concentration of between 5
15 x 10^{-8} M and 2 x 10^{-6} M, more preferably between 1 x 10^{-7} M and 1 x 10^{-6} M. Typically such a reduction in the equilibrium surface tension at a water/air interface may be achieved at a temperature ranging from 0°C to 50°C, especially room temperature. The change in equilibrium surface tension can be measured using a tensiometer following the method described in Cox *et al.*, *Langmuir,* 2007, 23, 7995-
20 8002.

In another embodiment, the hydrophobin may cause the surface shear elasticity at a water/air interface to increase to 300-700 mN/m, preferably 400-600 mN/m. Typically, such a surface shear elasticity at a water/air interface may be achieved using a
25 hydrophobin concentration of between 1 x 10^{-4} M and 0.01 M, preferably between 5 x 10^{-4} M and 2 x 10^{-3} M, especially 1 x 10^{-3} M. Typically, such a surface shear elasticity at a water/air interface may be achieved at a temperature ranging from 0°C to 50°C, especially room temperature. The change in equilibrium surface tension can be measured using a rheometer following the method described in Cox ef a/., *Langmuir,*
30 2007, 23, 7995-8002.

In some embodiments, the hydrophobins used in the present invention are biosurfactants. Biosurfactants are surface-active substances synthesised by living cells. They have the properties of reducing surface tension, stabilising emulsions,
35 promoting foaming and are generally non-toxic and biodegradable.

Examples of specific hydrophobins useful in the compositions of the present invention are **listed** in Table 1 below.

Table 1

Organism	**Gene,** Protein name	NCB! accession code and version number
Agaricus bisporus	ABH3	Y14602.1
Agaricus bisporus	HYPB	Y15940.1
Aspergillus fumigatus	HYP1 /RODA	L25258.1, U06121.1
Aspergillus fumigatus	RODB	AY057385.1
Aspergillus niger	**A_NIGi**	XM_0G1394993.1
Aspergillus oryzae	HYPB	AB097448.1
Aspergillus oryzae	ROLA	AB094496.1
Aspergillus terreus	A_TER	**XM_001213908.1**
Cladosporium fulvum	HCF-5	AJ133703.1
Cladosporium fulvum	HCF-6	AJ251294.1
Cladosporium fulvum	HCF-3	AJ566186.1
Cladosporium fulvum	HCF-1	X98578.1
Cladosporium fulvum	HCF-2	AJ133700.1
Cladosporium fulvum	HCF-4	AJ566187.1
Cladosporium herbarum	HCH-1	AJ496190.1
Claviceps fusiformis	CFTH1J-III	AJ133774.1
Claviceps fusiformis	CLF	CAB61236.1
Claviceps purpurea	CLP	CAD10781.1
Claviceps purpurea	CPPH1J-V	AJ418045.1
Coprinus cinereus	COH1	Y10627.1
Coprinus cinereus	COH2	Y10628.1
Cryphonectria parasitica	CRP	L09559.1
Dictyonema glabratum	DGH3	AJ320546.1
Dictyonema glabratum	DGH2	AJ320545.1
Dictyonema glabratum	DGH1	AJ320544.1
Emericella nidulans	RODA	M61113.1
Emericella nidulans	DEWA	U07935.1
Flammulina velutipes	FVH1	AB026720.1
Flammulina velutipes	FvHYDI	AB126686.1
Gibberella moniliformis	HYD5, GIM	AY158024.1
Gibberella moniliformis	HYD4	AY155499.1
Gibberella moniliformis	HYD1	AY155496.1
Gibberella moniliformis	HYD2	AY155497.1
Gibberella moniliformis	HYD3	AY155498.1
Gibberella zeae	GIZ, FG01831.1	XP_382007.1
Lentinula edodes	Le.HYDI	AF217807.1
Lentinula edodes	Le.HYD2	AF217808.1
Magnaporthe grisea	MGG4	XM_364289.1
Magnaporthe grisea	MGG2	XM_001522792.1
Magnaporthe grisea	MHP1 , MGG1	AF126872.1
Magnaporthe grisea	MPG1	L20685.2
Metarhizium anisopliae	SSGA	M85281.1
Neurospora crassa	NCU08192.1	AABX01000408.1
Neurospora crassa	EAS	AAB24462.1

Ophiostoma ulmi	CU	U00963 .1
Paracoccidioides brasiiensis	PbHYD2	AY427793 . 1
Paracoccidioides brasiiensis	PbHYDI	AF526275.1
Passalora fulva	PF3	CAC27408. 1
Passalora fulva	PF1	CAC27407.1
Passalora fulva	PP2	CAB3931 2.1
Pholiota narneko	PNH2	AB0791 29. 1
Phoiiota narneko	PNH1	AB0791 28. 1
Pisolithus linctorius	HYDPt-1	U29605.1
Pisolithus iinctorius	HYDPt-2	U29606.1
Pisolithus tinctorius	HYDPt-3	AF09751 6.1
Pleurotus ostreatus	P0H2	Y 14657. 1
Pleurotus ostreatus	P0H3	Y 16881 .1
Pleurotus ostreatus	VMH3	AJ2381 48. 1
Pleurotus ostreatus	P0H1	Y 14656. 1
Pleurotus ostreatus	FBHI	AJ004883.1
Schizophyllum commune	SC4	M32330. 1
Schizophyllum commune	SC1 , 1G2	X00788. 1
Schizophyllum commune	SC6	AJ007504. 1
Schizophyllum commune	SC3	AAA96324.1
Talaromyces thermophilus	TT1	
Trichoderma harzianum	QID3	X71 9 13.1
Trichoderma harzianum	SRH1	Y 11841 .1
Trichoderma reesei	HFB!!	P79073. 1
Trichoderma reesei	HFBI	P52754. 1
Tricholoma terreum	HYD1	AY048578. 1
Verticillium dahliae	VED	AAY891 0 1.1
Xanthoria ectaneoides	XEH1	AJ250793.1
Xanthoria parietina	XPH1	AJ250794. 1

Fusion Proteins

The definition of hydrophobin in the context of the present invention includes fusion proteins of a hydrophobin and another polypeptide as well as conjugates of hydrophobin and other molecules such as polysaccharides.

In one embodiment, the hydrophobin is a hydrophobin fusion protein. In this specification the term "fusion protein" means a hydrophobin sequence (as defined and exemplified above) bonded to a further peptide sequence (described herein as "a fusion partner") which does not occur naturally in a hydrophobin.

In one embodiment, the fusion partner may be bonded to the amino terminus of the hydrophobin core, thereby forming the group $(Yi)_m$- In this embodiment, **m** may range from 1 to 2000, preferably 2 to 1000, more preferably 5 to 500, even more preferably 10 to 200, still more preferably 20 to 100.

In one embodiment, the fusion partner may be bonded to the carboxyl terminus of the hydrophobin core, thereby forming the group $(Y_2)_n$. In this embodiment, n may range from 1 to 2000, preferably 2 to 1000, more preferably 5 to 500, even more preferably
5 10 to 200, still more preferably 20 to 100.

In another embodiment, fusion partners may be bonded to both the amino and carboxyl termini of the hydrophobin core. In this embodiment, the fusion partners may be the same or different, and preferably have amino acid sequences having the
10 number of amino acids defined above by the preferred values of m and n.

In one embodiment, the hydrophobin is not a fusion protein and m and n are 0.

Class I and II hydrophobins

15

In the art, hydrophobins are divided into Classes I and II. It is known in the art that hydrophobins of Classes I and II can be distinguished on a number of grounds, including solubility. As described herein, hydrophobins self-assemble at an interface (especially a water/air interface) into amphipathic interfacial films. The assembled
20 amphipathic films of Class I hydrophobins are generally re-solubilised only in strong acids (typically those having a pK_a of lower than 4, such as formic acid or trifluoroacetic acid), whereas those of Class II are soluble in a wider range of solvents.

25 In one embodiment, the hydrophobin is a Class II hydrophobin. In another embodiment, the hydrophobin is a Class I hydrophobin.

In one embodiment, the term "Class II hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property
30 at a water/air interface, the assembled amphipathic films being capable of redissolving to a concentration of at least 0.1% (w/w) in an aqueous ethanol solution (60% v/v) at room temperature. In contrast, in this embodiment, the term "Class I hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property but which does not have this specified
35 redissolution property.

In another embodiment the term "C!ass si hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property at a water/air interface and the assembled amphipathic films being capable of redissoiving to a concentration of at least 0.1% (w/w) in an aqueous sodium dodecy! sulphate solution (2% w/w) at room temperature. In contrast, in this embodiment, the term "Class I hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property but which does not have this specified redissolution property.

Hydrophobins of Classes I and II may also be distinguished by the hydrophobicity / hydrophiiicity of a number of regions of the hydrophobin protein.

In one embodiment, the term "Class II hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property and in which the region between the residues B_3 and B_4, *i.e.* the moiety $(X_3)_c$, is predominantly hydo phobic. in contrast, in this embodiment, the term "Class 1 hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property but in which the region between the residues B_3 and B_4, *i.e.* the group $(X_3)_c$, is predominantly hydrophilic.

In one embodiment, the term "Class II hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property and in which the region between the residues B_7 and B_8, *i.e.* the moiety $(X_7)_g$, is predominantly hydrophobic. In contrast, in this embodiment, the term "Class I hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property but in which the region between the residues B_7 and B_8, *i.e.* the moiety $(X_7)_g$, is predominantly hydrophilic.

The relative hydrophobicity / hydrophiiicity of the various regions of the hydrophobin protein can be established by comparing the hydropathy pattern of the hydrophobin using the method set out in Kyte and Doolittle, *J. Moi. Biol.,* 1982, *157,* 105-132. According to the teaching of this reference, a computer program can be used to progressively evaluate the hydrophiiicity and hydrophobicity of a protein along its amino acid sequence. For this purpose, the method uses a hydropathy scale (based on a number of experimental observations derived from the literature) comparing the hydrophilic and hydrophobic properties of each of the 20 amino acid side-chains. The program uses a moving-segment approach that continuously determines the

average hydropathy within a segment of predetermined length as it advances through the sequence. The consecutive scores are plotted from the amino to the carboxy terminus. At the same time, a midpoint line is printed that corresponds to the grand average of the hydropathy of the amino acid compositions found in most of the sequenced proteins. The method is further described for hydrophobins in Wessels, *Adv. Microbial Physiol.* 1997, *38,* 1-45.

In one embodiment, the term "Class II hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property and in which the region between the residues B_3 and B_4, *i.e.* the moiety $(X_3)_c$, is predominantly hydrophobic. In contrast, in this embodiment, the term "Class I hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property but in which the region between the residues B_3 and B_4, *i.e.* the group $(X_3)_c$, is predominantly hydrophilic.

In one embodiment, the term "Class II hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property and in which the region between the residues B_7 and B_8, *i.e.* the moiety $(X_7)_g$, is predominantly hydrophobic. In contrast, in this embodiment, the term "Class I hydrophobin" means a hydrophobin (as defined and exemplified herein) having the above-described self-assembly property but in which the region between the residues B_7 and B_8, *i.e.* the moiety $(X_7)_g$, is predominantly hydrophilic.

The relative hydrophobicity / hydrophilicity of the various regions of the hydrophobin protein can be established by comparing the hydropathy pattern of the hydrophobin using the method set out in Kyte and Doolittle, *J. Mol. Biol.*, **1982,** *157,* 105-132 and described for hydrophobins in Wessels, *Adv. Microbial Physiol.* **1997,** *38,* 1-45.

Class II hydrophobins may also be characterised by their conserved sequences. In one embodiment, the Class II hydrophobins used in the present invention have the general formula (IV):

$$(Y_1)_n\text{-}B_1\text{-}(X_1)_a\text{-}B_2\text{-}B_3\text{-}(X_3)_c\text{-}B_4\text{-}(X_4)_d\text{-}B_5\text{-}(X_5)_e\text{-}B_6\text{-}B_7\text{-}(X_7)_g\text{-}B_8\text{-}(Y_2)_m \quad \text{(IV)}$$

wherein:

m and n are independently 0 to 200;

B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu, Asa, Ser, Thr, Met or Gly, at least 6 of the residues B_1 through B_8 being Cys;

a is 6 to 12;

c is 8 to 16;

d is 2 to 20;

e is 4 to 12; and

g is 5 to 15.

in the formula (IV), a is preferably 7 to 11.

In the formula (IV), c is preferably 10 to 12, more preferably 11.

In the formula (IV), d is preferably 4 to 18, more preferably 4 to 16.

In the formula (IV), e is preferably 6 to 10, more preferably 9 or 10.

In the formula (IV), g is preferably 6 to 12, more preferably 7 to 10.

In one embodiment, the Class II hydrophobins used in the present invention have the general formula (V):



$$(Y_1)_n\text{-}B_1\text{-}(X_1)_a\text{-}B_2\text{-}B_3\text{-}(X_3)_c\text{-}B_4\text{-}(X_4)_d\text{-}B_5\text{-}(X_5)_e\text{-}B_6\text{-}B_7\text{-}(X_7)_g\text{-}B_8\text{-}(Y_2)_m \quad \text{(V)}$$

wherein:

m and n are independently 0 to 10;

B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu or Ser, at least 7 of the residues B_1 through B_8 being Cys;

a is 7 to 11;

c is 11;

d is 4 to 18;

e is 6 to 10; and

g is 7 to 10.

In the formulae (IV) and (V), at least 7, and preferably all 8 of the residues B_1 through B_8 are Cys.

In the formulae (IV) and (V), when 7 of the residues B_1 through B_8 are Cys, it is preferred that the residues B_3 through B_7 are Cys.

In the formulae (IV) and (V), when 7 of the residues B_1 through B_8 are Cys, it is preferred that: (a) B_1 and B_3 through B_8 are Cys and B_2 is other than Cys; (b) B, through B_7 are Cys and B_8 is other than Cys, or (c) B_1 is other than Cys and B_2 through B_8 are Cys. When 7 of the residues B, through B_8 are Cys, it is preferred that the other residue is Ser, Pro or Leu. In one embodiment, B. and B_3 through B_8 are Cys and B_2 is Ser. in another embodiment, or B_1 through B_7 are Cys and B_8 is Leu. in a further embodiment, B_1 is Pro and B_2 through B_8 are Cys.

In the formulae (IV) and (V), preferably the group $(X_3)_c$ comprises the sequence motif 2ZXZ, wherein Z is an aliphatic amino acid; and X is any amino acid. In this specification the term "aliphatic amino acid" means an amino acid selected from the group consisting of glycine (G), alanine (A), leucine (L), isoleucine (I), valine (V) and proline (P).

More preferably, the group $(X_3)_c$ comprises the sequence motif selected from the group consisting of LLXV, ILXV, 1LXL, VLXL and VLXV. Most preferably, the group $(X_3)_c$ comprises the sequence motif VLXV.

In the formulae (IV) and (V), preferably the group $(X_3)_c$ comprises the sequence motif ZZXZZXZ, wherein Z is an aliphatic amino acid; and X is any amino acid. More preferably, the group $(X_3)_c$ comprises the sequence motif VLZVZXL, wherein Z is an aliphatic amino acid; and X is any amino acid.

In one embodiment, the hydrophobin is a polypeptide selected from SEQ ID NOs: 2, 4, 6, 8 or 10, or a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 99% sequence identity in the hydrophobin core to any thereof. By "the hydrophobin core" is meant the sequence beginning with the residue B_1 and terminating with the residue B_8.

In one embodiment, the hydrophobin is obtained or obtainable from fungi of the phylum *Ascomycota.* In one embodiment, the hydrophobin is obtained or obtainable from fungi of the genera *Cladosporium* (particularly C. *fulvum), Ophistoma* (particularly O. *ulmi), Cryphonectria* (particularly *C. parasitica), Trichoderma*

(particu!ariy *7. harzianum, T. longibrichiatum, T. asperellum, T. Koningiopsis, T. aggressivum, T. stromaticum* or *7. reesei), Gibberella* (particularly *G. moniliformis), Neurospora* (particularly *N. crassa), Maganaporthe* (particularly *M. grisea)* or *Hypocrea* (particularly *H. jecorina, H. atroviridis, H. virens* or *H lixii).*

5

In a preferred embodiment, the bycirophofain is obtained or obtainable from fungi of the genus *Trichoderma* (particularly *T. harzianum, T. longibrichiatum, T. asperellum, T. Koningiopsis, T. aggressivum, T. stromaticum* or *7. reesei).* In a particularly preferred embodiment, the hydrophobin is obtained or obtainable from fungi of the
10 species *7. reesei.*

In a more preferred embodiment, the hydrophobin is the protein selected from the group consisting of:
(a) HFBII (SEQ ID NO: 2; obtainable from the fungus *Trichoderma reesei);*
15 (b) HFB; (SEO ID NO: 4; obtainable from the fungus *Trichoderma reesei);*
(c) SC3 (SEQ ID NO: 6; obtainable from the fungus *Schizophyllum commune);*
(d) EAS (SEQ ID NO: 8; obtainable from the fungus *Neurospora crassa);* and
(e) TT1 (SEQ ID NO: 10; obtainable from the fungus *Talaromyces thermophiius);* or a protein having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at
20 least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 99% sequence identity in the hydrophobin core to any thereof.

In a more preferred embodiment, the hydrophobin is the protein encoded by the polynucleotide selected from the group consisting of:
25 (a) HFBII (SEQ ID NO: 1; obtainable from the fungus *Trichoderma reesei);*
(b) HFBi (SEQ ID NO: 3; obtainable from the fungus *Trichoderma reesei);*
(c) SC3 (SEQ ID NO: 5; obtainable from the fungus *Schizophyllum commune);*
(d) EAS (SEQ ID NO: 7; obtainable from the fungus *Neurospora crassa);* and
(e) TT1 (SEQ ID NO: 9; obtainable from the fungus *Talaromyces thermophiius);*
30 or the protein encoded by a polynucleotide which is degenerate as a result of the genetic code to the polynucleotides defined in (a) to (e) above.

In an especially preferred embodiment, the hydrophobin is the protein "HFBII" (SEQ ID NO: 2; obtainable from *Trichoderma reesei)* or a protein having at least 70%, at
35 least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 99% sequence identity in the hydrophobin core thereof.

In one embodiment, the hydrophobin may be present as an initial component of the composition. In another embodiment, the hydrophobin may be generated *in situ* in the composition (for example, by *in situ* hydrolysis of a hydrophobin fusion protein).

5

In an alternative embodiment, the hydrophobin may **be** replaced wholly or partially with a chaplin. Chaplins are hydrophobin-iike proteins which are also capable of self-assembly at a hydrophobic-hydrophi!ic interface, and are therefore functional equivalents to hydrophobins. Chaplins have been identified in filamentous fungi and
10 bacteria such as Actinomyceies and Streptomyces. Unlike hydrophobins, they may have only two cysteine residues and may form only one disulphide bridge. Examples of chaplins are described in WO 01/74864, US 2010/0151525 and US 2010/0099844 and in Talbot, *Curr. Biol.* 2003, *13,* R696-R698.

15 LIPOLYTIC ENZYME

In this specification the term 'lipolytic **enzyme'** is **defined** as **an enzyme** capable of acting on a lipid substrate to liberate a free fatty acid molecule. Preferably, the **lipolytic enzyme** is **an** enzyme capable of hydrolysing an ester **bond** in a lipid
20 substrate (particularly although not exclusively a triglyceride, **a** glycolipid **and/or a** phospholipid) to liberate a free fatty acid molecule. Examples of possible lipid substrate are described below.

The lipolytic enzyme used in the present invention preferably has activity on both
25 non-polar and polar lipids. The term "polar lipids" as used herein means phospholipids and/or glycolipids. Preferably, the term "polar lipids" as used herein means both phospholipids and glycolipids. Polar and non-polar lipids are discussed in Eliasson and Larsson, "Cereals in Breadmaking: A Molecular Colloidal Approach", publ. Marcel Dekker, 1993.

30

In particular, the lipolytic enzyme used in the present invention preferably has activity on the following classes of lipids: triglycerides; phospholipids, particularly but not exclusively phosphatidylcholine (PC) and/or N-acylphosphatidylethanolamine (APE); and glycolipids, particularly although not exclusively digalactosyl diglyceride (DGDG).

35

In this specification the term 'free fatty acid' means a compound of the formula R-C(=0)-OH wherein R is a straight- or branched chain, saturated or unsaturated,

hydrocarbyl group, the compound having a total of 4 to 40 carbon atoms, preferabiy 6 to 40 carbon atoms, such as at least 10 to 40 carbon atoms, for example 12 to 40, such as 14 to 40, 16 to 40, 18 to 40, 20 to 40 or 22 to 40 carbon atoms, more preferabiy 10 to 24, especially 12 to 22, particularly 14 to 13, for example 16 or 18 carbon atoms. In one particular embodiment, such an acyl group is an aikanoyl group. Alternatively, such an acyl group comprises an alkenoyl group, which may have, for example, 1 to 5 double bonds, preferably 1, 2 or 3 double bonds.

Suitably, the lipolytic enzyme for use in the present invention may have one or more of the following activities selected from the group consisting of: phospholipase activity (such as phosphoiipase A1 activity (E.G. 3.1.1.32) or phospholipase A2 activity (E.G. 3.1.1.4); glycolipa.se activity (E.G. 3.1.1.26), triacylglycerol hydrolysing activity (E.G. 3.1.1.3), lipid acyltransferase activity (generally classified as E.G. 2.3.1.x in accordance with the Enzyme Nomenclature Recommendations (1992) of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology), and any combination thereof. Such lipolytic enzymes are well known within the art.

Suitably, the lipolytic enzyme for use in the present invention may be a phospholipase (such as a phospholipase A1 (E.G. 3.1.1.32) or phospholipase A2 (E.G. 3.1.1.4)); glycolipase or galactolipase (E.G. 3.1.1.26), triacylglyceride lipase (E.G. 3.1.1.3). Such enzyme may exhibit additional side activities such as lipid acyltransferase side activity.

Preferably, the lipolytic enzyme for use in the present invention has triacylglycerol hydrolysing activity (E.G. 3.1.1.3).

A lipolytic enzyme may be categorised as belonging to one of three classes (GX, GGGX or Y) based on structure and sequence analysis of the oxyanion hole of the enzyme.

A "GX lipolytic enzyme" is one where the oxyanion hole-forming residue X of the enzyme is structurally well conserved and is preceded by a strictly conserved glycine.

A "GGGX enzyme" is one where there is a well conserved GGG pattern, followed by a conserved hydrophobic amino acid X and the backbone amide of glycine preceding the residue X forms the oxyanion hole.

A "Y lipolytic enzyme" in one in which the oxyanion hole is not formed by a backbone amide but by the hydroxy! group of a tyrosine side chain.

5 In one aspect, the present invention relates to the use of a GX lipolytic enzyme.

Suitably, the oxyanion hole forming residue X may be M, Q, F, S, T, A, L or 1. Preferably, the oxyanion hole forming residue X may be M, Q, F, S or T.

10 in one embodiment, the lipolytic enzyme may belong to one of the following alpha/beta hydrolase superfamilies abH23 (preferably abH23.01), abH25 (preferably 25.01), abH16 (preferably 16.01), abH18 (preferably abH18.01) and abH15 (preferably 15.01 or 15.02).

15 In one embodiment, the lipolytic enzyme may belong to one of the following alpha/beta hydrolase superfamilies abH23 (preferably abH23.01), abH25 (preferably 25.01), abH16 (preferably 16.01) and abH15 (preferably 15.02).

In one embodiment, preferably the lipolytic enzyme is classified as a member of the 20 abH23 superfamily, preferably as a member of the abH23.01 homologous family in the Lipase Engineering Database.

Details regarding these superfamilies may be found on the Lipase Engineering Database (http://www.led.uni-stuttgart.de/). When referring to the Lipase Engineering 25 database herein reference is made to version 3.0 of the database released on 10 December 2009.

In particular, in one embodiment a lipolytic enzyme may be considered to belong to the abH23 superfamily if it is a GX lipolytic enzyme from a filamentous fungus. 30 Preferably, a lipolytic enzyme is a GX lipolytic enzyme if the catalytic triad of the enzyme aligns with that of a lipase from *Rhizopus miehei,* such as swissprot P19515.

Examples of lipolytic enzymes belonging to the abH23 superfamily include those indicated in Table 2.

35

Table 2

abH23	Organism	NCB! accession code *and* version number* OR gi number
abH23.01 ***(Rhizomucor miehei*** iipase **like)**	*Arabidopsis thaliana*	**NP_1 97365 .1**
		AAL24204. 1
		42570528
		145362642
	Aspergillus awamori	BAA92937.3
		84028205
	Aspergillus clavatus	12 17 19262
	Aspergillus flavus	27525628
	Aspergillus fumigatus	70985264
		70987066
	Aspergillus nidulans	679021 18
		67537354
	Aspergillus niger	AAK60631 .1
		042807. 1
		1UWC_A
		2HL6_A
		1USW_A
		2BJH_A
		145252728
		110431 975
		145241 772
		109677003
		145251 976
		110431 973
	Aspergillus oryzae	**8376661 0**
		169771 817
		169768448
		1697801 30
		169774351
		BAA1 291 2.1
	Aspergillus parasiticus	**27525626**
	Aspergillus iamarii	**1241 08031**

	Aspergillus terreus	1 15402833
		1 15385463
		1 15400761
		115443274
	Aspergillus tubingensis	04281 5.1
	Brugia malayi	17059251 1
	Caenorhabditis briggsae	157761 233
		157761 241
		157755883
		157771 698
		1577631 72
		157747253
		1577591 79
		1577591 77
		157772997
		1577731 05
		157773031
		15777461 3
		15777461 7
		157772605
		15777461 9
		157774601
	Caenorhabditis elegans	1 15534096
		17552584
		7 1983228
		7 1983230
		7 1983236
		193207843
		1 15534067
		15851 8 185
		865751 43
		1 15534303
		72000668
		AAF60431 .2
		7 1994497
		T27056
		7 1994547

		CAB61 1 37.3
		193247829
	Chaetomium globosum	116206442
	Cyanobium sp.	19762731 0
	Cyanothece sp.	172037675
		17766391 5
		196246404
	Dictyostelium discoideum	60463496
		66825791
		AAM43784.1
	Dictyostelium discoideum AX4	66802624
	Fusarium oxysporum	143791 375
	Gibberella zeae	33621 223
		461 23057
	Magnaporthe grisea	39978263
	Nectria haematococca	CAC1 9602.1
	Neosartorya fischeri	1194991 43
		119480389
	Neurospora crassa	CAC28687.1
	Neurospora crassa QR74A	EAA32 130.1
	Oryza sativa	115463525
		125552085
		125577937
		115486491
		115473965
		125586239
		125543854
		1255351 66
		125559538
		115442095
		115453007
		BAB64204.1
		125529023
	Penicillium allii	31872092
	Penicillium camemberti	P25234
		1TI A
		1TIA_A

	Penicillium cyclopium	48429006
		AAF82375.1
	Penicillium expansum	AAG22769.1
	Phaeosphaeria nodorum	169595748
		169606904
	Physcomitrella patens	168020609
		168040480
		168037728
	Podospora anserina	17 1693635
	Populus frichocarpa	118482274
	Pyrenophora tntici-repentis	1891 9251 6
		189202058
	Rhizomucor miehei	P 1951 5.2
		3TGL
		5TGL
		4TGL
		1TGL
		5TGL_A
		4TGL_A
		1TGL_A
		3TGL_A
	Rhizopus arrhizus	1TIC_A
		AAF32408.1
		1TIC_B
	Rhizopus javanicus	73621 144
	Rhizopus microsporus	156470335
		166078592
	Rhizopus niveus	P21 811
		1LGY_A
		BAA31 548.1
		1LGY_B
		1LGY_C
	Rhizopus oryzae	AAS84458.1
		P61 872. 1
		1TIC_A
		94962082
		7 13901 09
	Rhizopus stolonifer	AAZ66864.1

	Synechococcus sp.	87301 494
	Thermomyces ianuginosus	059952.1
		1TI B
		1DTE_A
		1DT5_D
		1DU4_B
		1DT3_A
		1EIN_B
		1DT3_B
		1DT5_E
		1DT5_B
		1DT5_G
		1DT5_F
		1DT5_H
		1DT5_A
		1DT5_C
		1DTE_B
		1DU4_A
		1DU4_D
		1DU4_.C
		1EIN_C
		1EIN_A
		1GT6_A
	Triticum aestivum	CAD32696.1
		CAD32695.1
	Vitis vinifera	157336329
	Zea mays	194691 896
		194690642
		194706432
		194694588
		19469421 0

In this embodiment, preferably the oxyanion hole forming residue is a serine or threonine.

5 Preferably, the lipolytic enzyme belongs to the *Rhizopus miehei* like homologous family abH23.01 . Suitably, particularly preferred enzymes for use in the present invention may include any lipolytic enzymes classified in homologous family

abH23.01 from *Thermomyces* (preferably, *T. lanuginosus), Fusarium* (preferably *F. hetereosporum), Aspergillus* (preferably *A. tubiengisis* and/or *A. fumigatus)* and *Rhizopus* (preferably, *R. arrihzus),* preferably from *Thermomyces* (preferably, *T. lanuginosus), Fusarium* (preferably *F. hetereosporum),* or *Aspergillus* (preferably *A. tubiengisis).* Examples of such lipolytic enzymes include LIPEX™ (a *Thermomyces lanuginosus* lipolytic enzyme disclosed in WO 94/026 17 and shown herein as SEQ ID NO: 11, the *Fusarium heterosporum* lipolytic enzyme disclosed in WO 2005/08791 8 and shown herein as SEQ ID NO: 13 (available from Danisco A/S as Grindamyl POWERBAKE 4100™} and Lipase 3 (an *Aspergillus tubigensis* lipolytic enzyme disclosed in WO 98/45453 and shown herein as SEQ ID NO: 14).

In one embodiment of the present invention, a lipolytic enzyme may be considered to belong to the abH25 superfamily if the catalytic triad aligns with that of the *Moraxella* lipase 1 like lipolytic enzyme as shown in the swissprot protein knowledge base (http://www.expasy.org/sprot/ and http://www.ebi.ac.uk/swissprot/) under accession number P19833 - version of 26 July 2005.

Examples of lipolytic enzymes belonging to this family include those listed in Table 3.

Table 3

abH25	**Organism**	NCBi **accession code and version number*** **OR gi number**
abH25.01 ***(Moraxella* lipase 1 like)**	*Acidovorax delafieldii*	BAB86909.1
	Kineococcus radiotolerans	152967773
	Kineococcus radiotolerans SRS3021 6	EAM75386.1
	Moraxella sp.	P19833. 1
	Streptomyces albus	AAA53485.1
	Streptomyces ambofaciens	117164910
	Streptomyces coelicolor	AAD0931 5.1
		CAB69685. 1
	Streptomyces exfoliatus	1JFR_B
		1JFR_A
	Streptomyces griseus	182439251
	Thermobifida fusca	721 6 1287
		721 6 1286

	Thermobifida fusca DSM 43793	CAH1 7553.1
		CAH 17554.1

In this embodiment, preferably the oxyanion hole forming residue is M, Q, A, F, L or I.

in one embodiment of the present invention, a iipoiytsc enzyme may be considered to belong to the abH16 superfamify if the cataiytic triad aligns with that of *Streptomvces.*

Examples of lipolytic enzymes belonging to this family include those indicated in Table 4.

Table 4

abH16	Organism	NCBI accession code and version number* OR gi number
abH16.01 (*Streptomyces* lipases)	*Arthrobacter chlorophenolicus*	169176591
	Arthrobacter sp. FB24	116669612
	Corynebacterium diphtheriae	38232746
	Corynebacterium efficiens	25026650
		25026649
	Corynebacterium efficiens YS-314	BAC16904.1
		BAC16903.1
	Corynebacterium glutamicum	19551331
		145294142
		19551330
		145294141
	Frankia sp.	158312565
	Frankia sp. EAN1pec	EAN12331.1
	Nocardia farcinica	54025580
	Nocardioides sp.	119715399
	Nocardioides sp. JS614	EAO07564.1
	Propionibacterium acnes	50843543
		50843256
	Propionibacterium acnes P-37	CAA67627.1
	Rhodococcus sp.	111021394
		111024112
		111025204

		111025876
		111022422
		111024917
		40787231
	Rubrobacter xylanophilus	108805093
	Rubrobacter xylanophilus DSM 9941	EAN36909.1
	Streptomyces avermitilis	29833101
	Streptomyces avermitilis MA-4680	BAC74270.1
	Streptomyces cinnamoneus	AAB71210.1
	Streptomyces coelicolor	NP606008
	Streptomyces fradiae	148832709
	Streptomyces griseus	182439565
	Streptomyces pristinaespiralis	YP002199726
	Streptomyces sp.	197333608
	Streptomyces sviceus	197781872
	Synthetic construct	AA092397. 1

In this embodiment, preferably the oxyanion hole forming residue is T or Q.

In one embodiment of the present invention, a lipolytic enzyme may be considered to
5 belong to the abH 15 superfamily if the catalytic triad aligns with that of a GX
Burkholderia lipase.

Examples of lipolytic enzymes belonging to this family include those indicated in
Table 5 and LIPOMAX as shown herein as SEQ ID NO: 15.

10

Table 5

abH1 5	**Organism**	**NCBI accession code and version number* OR gi number**
abH1 5.02 *(Burkholderia cepacia* lipase like)	*Acidovorax avenae*	12061 2825
		16979451 5
		1266431 75
	Acinetobacter baumannii	193078538

		15851 7002
	Acinetobacter calcoaceticus	AAD29441 .1
		1581 20326
	Acinetobacier schindleri	1581 20327
	Acinetobacter sp.	50086294
	Acinetobacier sp. SY-01	AAP44577. 1
	Aeromonas hydrophila	1176 18653
	Aeromonas salmonicida	145300587
	Alcanivorax borkumensis	110834836
		1961 94968
	Alcanivorax sp.	1961 931 33
	Alteromonas macleodii	88795738
	Azotobacter vinelandii AvOP	EAM0521 4.1
		115358044
		118695660
		171316092
		170702796
	Burkholdena ambifaria	171320247
		124875244
		107026795
		11871 3500
		84354072
		198038844
	Burkholdena cenocepacia	190607421
	Burkholdena cenocepacia AU 1054	EAM08623. 1
	Burkholderia cenocepacia HI2424	EAM 18550. 1
		AAY86757.2
		1167391 50
		161406799
		10IL_B
		1HQD_A
		4LIPJD
		P22088.2
		10IL_A
		4LIP_E
	Burkholdena cepacia	1YS2_X
	Burkholdena cepacia KCTC 2966	AAT85572. 1
		4631 9469
	Burkholderia cepacia R1808	4631 9468

	Burkholderia cepacia R18194	4631 2540
	Burkholderia cepacia ST-200	BAD1 3379.1
	Burkholderia dolosa	8436031 3
		1TAH_A
		1TAH_C
		1TAH _B
		1TAHJD
		1QGE _E
	Burkholderia glumae	2ES4_A
		8361 8505
		537 1 5898
		8361 8339
	Burkholderia mallei	167003692
		67636935
	Burkholderia mallei 10399	67635666
	Burkholderia mallei FMH	69987887
		67640408
	Burkholderia mallei GB8 horse 4	67642620
	Burkholderia mallei JHU	70001349
	Burkholderia mallei NCTC 10247	67645935
		16 1521 2 10
	Burkholderia multivorans	16 15251 17
	Burkholderia multivorans RG2	AAW30 196. 1
	Burkholderia multivorans Uwc 10	AAZ39650.1
		167573565
		167568063
		167567050
	Burkholderia oklahomensis	1675741 27
		53722762
		126445060
		9991 1132
		1001 26424
		16791 581 5
		126442397
		157806477
		134281 779
		7681 8459
		100231 475
	Burkholderia pseudomallei	9990851 5

		100059930
		53723336
		100121879
		167744369
		184212969
		167908322
		167725450
	Burkholderia pseudomallei 1655	67671 904
		67670022
	Burkholderia pseudomallei 1710a	67684997
		67681 352
	Burkholderia pseudomallei 668	677351 59
	Burkholderia pseudomallei Pasteur	67755633
		67753658
	Burkholderia pseudomallei S13	67759470
	Burkholderia sp. 383	78063020
	Burkholderia sp. HY-10	154091354
	Burkholderia sp. 99-2-1	AAV34204. 1
	Burkholderia sp. MC16-3	AAV34203.1
	Burkholderia thailandensis	8371 7248
		167577201
		8371 6483
		167579206
		16761 7325
		167840423
	Burkholderia ubonensis	167583926
	Burkholderia vietnamiensis	134293086
		134293087
	Burkholderia vietnamiensis G4	EAM26790. 1
		67548784
		EAM26789. 1
	Chromobacterium violaceum	344981 69
	Chromobacterium violaceum ATCC 12472	AAQ60384. 1
	Burkholderia glumae	1CVL_A
	Cupriavidus taiwanensis	194289366
	Dehalococcoides sp.	16381 3742
	Gamma proteobacterium	1982621 10
		1982621 37

	Hahella chejuensis	83646958
	Listonella anguillarum	19731 3280
	Listonella anguillarum M93Sm	AAY261 46.2
		1493761 15
	Marinobacter algicola	149378244
	Marinomonas sp.	871 19903
		149908369
		14991 1484
	Moritel!a sp.	149909327
	Myxococcus xanthus	108756922
		945001 83
	Oceanobacter sp.	94501 726
		90409701
	Photobactenum profundum	5430361 2
	Photobacterium profundum ss9	CAG23805.1
	Photobactenum sp.	89072072
	Plesiocystis pacifica	149921 436
	Proteus mirabilis	197284877
	Proteus sp.	1841 91073
	Proteus vulgaris	AAB01 071 .1
		AAC34733. 1
		P26876.2
		BAA091 35.1
		AAF641 56.1
		BAA231 28.1
		1EX9_A
		1071 0241 1
		152989672
	Pseudomonas aeruginosa	152983830
	Pseudomonas aeruginosa KCTC 1637	AAT85570.1
	Pseudomonas entomophila	104783837
		77456799
		77459293
		AAC1 5585. 1
	Pseudomonas fluorescens	707341 19
		23058245
	Pseudomonas fluorescens PfO-1	23061 908
	Pseudomonas fragi	CAC071 91.1

		P08658.2
		AAA25879. 1
	Pseudomonas luteola	AAC0551 0.1
		146307587
		146306794
	Pseudomonas mendocina	AAM1 4701 .1
		167035900
		119858840
		170723807
		26991534
	Pseudomonas putida	148549934
	Pseudomonas putida KT2440	AAN 70423. 1
		4LIP_E
		1891 7871 1
	Pseudomonas sp.	1891 7871 3
	Pseudomonas sp. 109	P26877. 1
	Pseudomonas sp. KFCC1 081 8	AAD22078. 1
	Pseudomonas sp. KWI-56	P25275. 1
	Pseudomonas sp. SW-3	AAG47649.2
	Pseudomonas stutzeri	146282376
	Pseudomonas wisconsinensis	AAB53647.1
	Psychrobacter cryohalolentis	93005273
	Psychrobacter cryohalolentis K5	EA0 10600.1
	Psychrobacter sp.	148652775
	Ralstonia eutropha	113867341
	Ralstonia metallidurans	22979988
		153885935
	Ralstonia pickettii	121531 370
	Ralstonia sp. *M1*	AAR1 3272. 1
	Rhodoferax ferrireducens	899021 27
	Shewanelia denitrificans	91792458
	Shewanelia denitrificans OS-21 7	69944965
	Shewanelia denitrificans 0S21 7	EAN69301 .1
	Shewanelia frigidimarina	114564999
	Shewanelia frigidimarina NCIMB 400	EAN741 11.1
	Shewanelia woodyi	118073371
	Sorangium cellulosum	162451 743
		AAT51 282.1
	Synthetic construct	AAT51 165. 1

	Vibrio alginolyticus	91225988
	Vibrio angustum	90580697
	Vibrio campbellii	163801 151
		P15493.2
		AAA1 7487. 1
		150423294
		11621 9797
		153801 593
		15321 5150
	Vibrio cholerae	11621 4571
	Vibrio cholerae M0 10	75830993
	Vibrio cholerae RC385	75821 182
	Vibrio cholerae V51	75819240
	Vibrio cholerae V52	7581 6524
		156974975
	Vibrio harveyi	1538341 78
		28897955
	Vibrio parahaemolyticus	153837472
	Vibrio shilonii	149187907
		116184955
	Vibrio sp.	861 44587
	Vibrio sp. Ex25	75855688
	Vibrio splendidus	84385385
		376801 74
	Vibrio vulnificus	27365668
	Vibrio vulnificus CKM-1	AAQ04476. 1
	Vibrio vulnificus CMCP6	AA01 0723. 1
	Vibrionales bacterium	148974047
		22996002
	Xylella fastidiosa	281 98381
	Xylella fastidiosa Ann-1	EA03 1309.1
	Xylella fastidiosa Temecula1	AA028344.1
	Yersinia enterocolitica	1234421 25
	Yersinia mollaretii ATCC 43969	77961 583

abH15	Organism	NCBI accession coda and version number* OR gi number
	Ailuropoda melano!euca	6251 1068
		583391 72
		533391 74
		583391 76
		583391 78
	Alouaita seniculus	583391 80
		AAF1 7667. 1
		AAF8701 2.1
		D86367
		26451 003
		AAD31 339. 1
	Arabidopsis thaliana	42571 431
		1846251 2
	Ateles geoffroyi	1846251 4
	Bacillus anthracis	30262592
	Bacillus anthracis Ames	AAP26455. 1
		521 42888
		42781 684
		1681 39359
		1681 341 90
		167938472
		1681 58861
		166993225
		19604361 8
abH1 5.01 *(Staphylococcus aureus* lipase like)	*Bacillus cereus*	196040277

	Bacillus cereus G924 1	EAL 12983. 1
	Bacillus sp. 42	AAV351 02. 1
	Bacillus sp. L2	AAW47928.1
	Bacillus sp. TP10A. 1	AAF63229.1
	Bacillus sp. Tosh	AAM21775. 1
		757641 33
		49477789
	Bacillus thuringiensis	118477999
	Bacillus thuringiensis A TCC 35646	EA051 633.1
	Bacillus welhenstephanensis	163940476
	Balaenoptera borealis	081 2 180A
		55583872
	Balaenoptera physalus	1104245A
		164597876
	Bos frontalis	116256079
		6251 1051
	Bos grunniens	119675392
		270861 1
		6063098
	Bos indicus	164597854
		8341 6245
		8341 6247
		30794288
		134244277
		164597862
		8341 6249
		59797396
	Bos taurus	12663221 3

		6063096
		83416241
		60651 145
		13431390
	Bubalus bubalis	296143
		58339182
		58339184
	Caliicebus moloch	58339183
		17368913
		21449837
	Callithrix jacchus	21449839
		6251 1040
	Camelus dromedarius	126567081
		312196
	Canis lupus	50978904
		190683030
		83416243
		155183991
		6063094
		15 10 157A
		60687495
	Capra hircus	126632219
		6251 1092
	Cavia porcellus	7677454
	Cebus albifrons	1 16634246
		3024641
	Cervus elaphus	70909960
	Cloning vector	12584848

		153941 353
		168178255
		187932762
		1681 79769
		153940345
		1681 85824
		170759344
		188588446
		1681 86291
		170756926
		14838001 8
		170758348
		1681 83734
		188590654
		187935767
		188587698
		148378855
		1681 84078
	Clostridium botulinum	170757848
		118443364
	Clostridium novyi	11844321 1
		187777968
	Clostridium sporogenes	187779336
	Clostridium tetani	2821 0658
	Clostridium tetani Massachusetts	AA035539.1
	Deinococcus radiodurans	C75533
	Delphinus delphis	6251 1070
	Elephantidae gen.	1509285A

		126352373
		170931 OA
		156723467
		56786671
		168693409
		197941 001
		111606634
	Equus caballus	111606636
		571 63879
	Fe!is catus	567042
	Galago senegalensis	17368901
	Geobacillus kaustophilus	56420521
		67906830
	Geobacillus sp. (Strain T1)	JC8061
	Geobacillus sp. T1	AAO92067.2
		AAF4021 7.1
		1JI3_B
		1JI3_A
		AAL28099. 1
		117373028
		JW0068
		1KU0_A
		1KU0_B
	Geobacillus stearothermophilus	AAX1 1388.1
	Geobacillus thermocatenulatus	CAA64621 .1
		AAD30278. 1
		113431 924
	Geobacillus thermoleovorans	AAM21 774. 1

		83939852
	Geobacillus thermoleovorans IHI-91	AAN7241 7.1
		1102651 50
		2DSN..A
	Geobacillus zalihae	2Z5G_A
	Giraffa camelopardalis	6251 1039
	Hippopotamus amphibius	6251 1038
		1AXI_A
		1HGU_A
		1KF9_A
		711074A
		10334861
		4503083
		1Z7C_A
		34784701
		181127
		731 144A
		36544
		12545376
		12545381
		1302781 2
		1HWG_A
		11961 4650
		47121568
		3HHR_A
		47121579
		1HWH_A
	Homo sapiens	1403262B

		3 1905
		11961 4648
		1302781 4
		1403262A
		1302781 6
		4503991
		49456759
		49456803
		1831 77
		1 1961 4662
		13027822
		1 1961 4661
		1 1961 4666
	Lactobacillus casei CL96	AAP02960.1
		1 10338953
	Lama pacos	58601 0
	Loxodonta africana	134706
		538541 58
		541 24352
		538541 63
	Macaca assamensis	538541 65
		112293303
		2931 11
		112293293
		681 36596
		1 14052777
		11405271 7
	Macaca mulatta	114052929

		1 12293289
		112293299
		681 36594
		2500855
		1091 16855
		1091 49084
		1091 48991
	Mesocricetus auratus	58601 2
	Monodelphis domestica	741 36533
		6679997
	Mus musculus	4096656
	Nannospalax ehrenbergi	62510957
		134709
		4684921 5
	Neovison vison	164254
		538541 3 1
		53854129
		53854133
		53854135
		53854137
	Nomascus leucogenys	53854139
	Nycticebus pygmaeus	17368910
	Oryctolagus cuniculus	1174399
		115463847
	Oryza sativa	125552313
		94183527
		94406690
	Ovis aries	94183483

		941 8351 9
		155001 235
		941 83467
		1666694
		941 83402
		941 83398
		941 83424
		126632207
		941 83444
		18051 46A
		941 83426
		941 83523
		10051 82A
		941 83400
		941 8351 1
		941 8341 0
		12663221 1
		941 83452
		165887
		1167351 58
		941 83438
		57527824
		941 83495
		941 83507
		941 8351 5
		941 83475
		126632209
		941 83420

		94183432
		83955026
		94183430
	Paenibacillus larvae	167465325
		20140016
		20140015
		114669972
		114669970
		114669980
		114669998
		114669984
		114669978
		114669976
		114669996
		114669982
		114670000
		114669918
		114669948
		114669944
		114669938
		571 13881
		114669920
		114669930
		114669994
		114669992
		114669990
		114670016
	Pan troglodytes	114670014

		55645705
		114669905
		114669936
		571 13891
		114669942
		114669934
		114669940
		571 13885
		281 88745
		11466991 5
		114669922
		114669932
		114670004
	Physcomitrella patens	162691 248
		583391 90
		583391 92
	Pithecia pithecia	583391 95
		538541 4 1
		541 24350
		538541 46
	Pygathrix nemaeus	538541 48
		13471 7
		77861 9 10
		149054569
	Rattus norvegicus	149054567
		538541 50
		538541 52
	Rhinopithecus roxellana	538541 54

		53854156
	Saimiri boliviensis	17368174
	Shuttle vector	2342750
		153104
		88193885
		1314205A
		49482354
		57652458
		83682315
		120864890
		83682355
		586027
		83682335
		15923101
		154736704
		83682395
		83682375
		83682371
		120864986
		120865151
		83682327
		120865143
		120864794
		120865004
		120864887
		120865236
		46695
	Staphylococcus aureus	82750020

		154736702
		120865077
		83682365
		83682377
		120865094
		120865232
		83682345
		1208651 40
		83682333
		83682369
		83682331
		83682339
		120865030
		120864975
		1208651 01
		120865021
		8368231 1
		151220267
		148266538
		133853458
		83682383
		1891 69989
		161508379
		120864978
		1905280A
		83682307
		21281 813
		83682309

		83682363
		83682397
		120864800
		1208651 83
		120864824
		154736696
		83682379
		120864797
		120864834
		83682337
		120865080
		83682389
		154736698
		154736692
		1208651 23
		83682385
		83682359
		83682351
		BAB96455.1
		BAB43769. 1
		S68970
		AAD52059. 1
		P65289.2
		57651 062
		8402821 8
		P 10335. 1
		AAK291 27.1
		B89797

		871 621 30
		2 1232026
		57651 244
		148266743
		158347635
		49484866
		84029334
		49482552
		1480567
		82752249
	Staphylococcus aureus MW2	Q8NYC2.1
	Staphylococcus aureus Mu50	Q99QX0
		643453
	Staphylococcus carnosus	643451
		274671 03
		193888386
		Q0251 0
		82654954
		AAC38597. 1
		AAC67547. 1
		57865775
		57865971
		27469321
		274671 63
	Staphylococcus epidermidis	57865673
	Staphylococcus epidermidis 9	AAA1 9729.1
		AAO06046.1
		AAO03782.1
	Staphylococcus epidermidis A TCC 12228	AAO03878. 1
		AAO03842. 1
		707251 69
	Staphylococcus haemolyticus	AAF21 294. 1
		2HIHA_A
	Staphylococcus hyicus	P04635. 1

		AAT34964. 1
		73663604
	Staphylococcus saprophyticus	73661 811
	Staphylococcus simulans	CAC83747.1
		AAG35723.1
		BAD90561 .1
		BAD90565. 1
	Staphylococcus warneri	BAD90562. 1
		551 988
		551 987
		AAG35726.1
	Staphylococcus xylosus	52854061
		124268
	Streptococcus sp.	47072
		46361 729
		164478
		166835929
		5723331 1
		16081 12A
		1312298A
		5723331 3
		57233321
		475231 20
	Sus scrofa	912486
		33341 802
		6671 284
		14582904
		6081 0119
		61364449
		6082741 2
		6081 5489
		305841 41
		60655785
	Synthetic construct	6671 282
		12964200
	Tragulusjavanicus	129641 98
	Trichosurus vulpecula	391 5004

	Uncultured bacterium	145965989
	Uncultured bacterium	145965991
	Vitis vinifera	15732981 9
		158346762
		16634381 4
	Vu!pes lagopus	JS0429
	Vuipes vulpes	134722

Throughout the specification examples of enzymes falling into a particular superfamily and/or homologous family in accordance with the Lipase Engineering Database version 3.0 are provided. In one embodiment of the present invention, the lipolytic enzyme of the present invention may be selected from any one or more of the lipolytic enzymes in these exemplified groups.

In another embodiment, the lipolytic enzyme for use in the present invention may be from one or more of the following genera: *Thermomyces* (preferably *T. lanuginosus), Thermobifida* (preferably, *T. fusea), Pseudomonas* (preferably *P. alcaligenes)* and *Streptomyces* (preferably S. *pristinaespiralis).*

Suitably, the lipolytic enzyme may comprise one of more of the following amino acid sequences:

a) SEQ ID NO: 11;
b) SEQ ID NO: 15;
c) SEQ !D NO: 16;
d) SEQ ID MO: 17;
e) an amino acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to any one of the amino acid sequences defined in a) to d); or
f) an amino acid sequence as set forth in any one of a) to d) except for one or several modifications *(i.e.* deletions, substitutions and/or insertions), such as 2, 3, 4, 5, 6, 7, 8, 9 amino acid modifications, or more amino acid modifications such as 10 and having lipolytic enzyme activity.

Suitably, the lipolytic enzyme may belong to the abH 15 superfamily, preferably the abH 15.01 superfamily.

5 Suitably, the lipolytic enzyme may comprise one of more of the following amino acid sequences

a) SEQ ID NO. 25;
b) SEQ ID NO: 26;
10 c) SEQ ID NO.25 lacking the signal peptide as indicated in Figure 36;
d) an amino acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably-at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%,
15 preferably at least 98%, or preferably at least 99% identity to any one of the amino acid sequences defined in a) to c); or
e) an amino acid sequence as set forth in any one of a) to c) except for one or several modifications *(i.e.* deletions, substitutions and/or insertions), such as 2, 3, 4, 5, 6, 7, 8, 9 amino acid modifications, or more amino acid
20 modifications such as 10 and having lipolytic enzyme activity.

Suitably, the lipolytic enzyme may comprise a lipase cloned from *Geobacillus* species, preferably *G stearothermophilus* strain T1 (GeoT1), such as that shown in SEQ ID NO: 25. In some embodiments the lipolytic enzyme, such as GeoT1, is fused
25 to the carboxy-terminus of the catalytic domain of a bacterial cellulose such as that shown in SEQ ID NO: 26. In some embodiments, the bacterial cellulase is derived from a *Bacillus* strain deposited as CBS 670.93 (referred to as BCE103) with the Central Bureau voor Schimmelcultures, Baam, The Netherlands. In some embodiments the lipolytic enzyme, such as GeoT1, is connected to the BCE103
30 cellulase by a cleavable linker. Thus in some embodiments the lipolytic enzyme, such as GeoT1, is not a fusion protein.

Suitably, the lipolytic enzyme may belong to the abH 18 superfamily, preferably the abH 18.01 superfamily.

35

Suitably, the lipolytic enzyme may comprise one of more of the following amino acid sequences

f) SEQ ID NO: 27;

g) SEQ ID NO: 28;

h) SEQ ID NO: 27 lacking the signal peptide as indicated in Figure 36;

i) an amino acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to any one of the amino acid sequences defined in a) to c); or

j) an amino acid sequence as set forth in any one of a) to c) except for one or several modifications *(i.e.* deletions, substitutions and/or insertions), such as 2, 3, 4, 5, 6, 7, 8, 9 amino acid modifications, or more amino acid modifications such as 10 and having lipolytic enzyme activity.

Suitably, the lipolytic enzyme may comprise a lipase cloned from *Bacillus subtilis,* preferably a lipaseA (LipA) from *Bacillus subtilis* such as that shown in SEQ ID NO: 27. In some embodiments, the lipolytic enzyme, such as LipA, is fused to the carboxy-terminus of the catalytic domain of a bacterial cellulose such as that shown in SEQ ID NO:28. In some embodiments, the bacterial cellulase is derived from a Bacillus strain deposited as CBS 670.93 (referred to as BCE103) with the Central Bureau voor Schimmelcultures, Baam, The Netherlands. In some embodiments the lipolytic enzyme, such as LipA, is connected to the BCE103 cellulase by a cleavable linker. Thus in some embodiments the lipolytic enzyme, such as LipA, is not a fusion protein.

In one aspect, as used herein, a "lipase", "lipase enzyme", "lipolytic enzymes', "lipolytic polypeptides", or "lipolytic proteins" refers to an enzyme, polypeptide, or protein exhibiting a lipid degrading capability such as a capability of degrading a triglyceride or a phospholipid. The lipolytic enzyme may be, for example, a lipase, a phospholipase, an esterase or a cutinase. As used herein, lipolytic activity may be determined according to any procedure known in the art (see, *e.g.,* Gupta *et al.*, *Biotechnol. Appl. Biochem.,* **2003,** 37:63-71 ,; U.S. Pat. No. 5,990,069; and International Publication No. WO 96/18729).

In one aspect, the present invention provides a detergent or cleaning composition comprising:

a) a polypeptide as shown in SEQ ID NO: 17 or a fragment thereof having lipase activity;
b) a polypeptide having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 17 and having lipase activity; or
c) a polypeptide as set forth in SEQ ID NO: 17 except for one or several modifications (*i.e.* deletions, substitutions and/or insertions), such as 2, 3, 4, 5, 6, 7, 8, 9 amino acid modifications, or more amino acid modifications such as 10 and having lipase activity;
d) a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 23 or by a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;
e) a polypeptide having lipase activity encoded by a nucleic acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 23 or to a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;
f) a polypeptide having lipase activity encoded by a nucleic acid sequence which hybridizes under stringent conditions to the complement of the nucleic acid sequence of SEQ ID NO: 23; or
g) a polypeptide obtainable (preferably obtained) from *Streptomyces* (preferably *S. pristinaespiralis)* having lipase activity.

Suitably, the polypeptide may be present in a concentration of 0.01 to 2 ppm by weight of the total weight of the composition. The composition may further comprise one or more enzymes selected from the group consisting of a protease, an amylase, a glucoamylase, a maltogenic amylase, a non-maltogenic amylase, a lipase, a cutinase, a carbohydrase, a celiulase, a pectinase, a mannanase, an arabinase, a

gaiactanase, a xyianase, an oxidase, a iaccase, a peroxidase, and an acyl transferase.

Suitably, the composition may comprise one or more surfactants, such as one or more surfactants selected from the group consisting of non-ionic (including semi-polar), anionic, cationic and zwitterionic.

Suitably, the composition may be in powder form or may be in liquid form.

The present invention further provides a method of removing a lipid-based stain from a surface by contacting the surface with a composition comprising:

a) a polypeptide as shown in SEQ ID NO: 17 or a fragment thereof having lipase activity;
b) a polypeptide having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 17 and having lipase activity; or
c) a polypeptide as set forth in SEQ ID NO: 17 except for one or several modifications (*i.e.* deletions, substitutions and/or insertions), such as 2, 3, 4, 5, 6, 7, 8, 9 amino acid modifications, or more amino acid modifications such as 10 and having lipase activity;
d) a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 23 or by a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;
e) a polypeptide having lipase activity encoded by a nucleic acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 23 or to a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;

f) a polypeptide having lipase activity encoded by a nucleic acid sequence which hybridizes under stringent conditions to the compiement of the nucleic acid sequence of SEQ ID NO: 23; or

g) a polypeptide obtainable (preferably obtained) from *Streptomyces* (preferably *5. pristinaespiralis)* having lipase activity.

In another aspect, the present invention provides the use of a composition comprising:

a) a polypeptide as shown in SEQ ID NO: 17 or a fragment thereof having lipase activity;

b) a polypeptide having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 17 and having lipase activity; or

c) a polypeptide as set forth in SEQ ID NO: 17 except for one or several modifications *(i.e.* deletions, substitutions and/or insertions), such as 2, 3, 4, 5, 6, 7, 8, 9 amino acid modifications, or more amino acid modifications such as 10 and having lipase activity;

d) a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 23 or by a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;

e) a polypeptide having lipase activity encoded by a nucleic acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 23 or to a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;

f) a polypeptide having lipase activity encoded by a nucleic acid sequence which hybridizes under stringent conditions to the complement of the nucleic acid sequence of SEQ ID NO: 23; or

g) a polypeptide obtainable (preferably obtained) from *Streptomyces* (preferably *S. pristinaespiralis)* having lipase activity,

in cleaning and/or in a detergent. For example, such use may be to reduce or remove lipid stains from a surface.

In another aspect, the present invention provides a method of cleaning a surface, comprising contacting the surface with a composition comprising:

a) a polypeptide as shown in SEQ ID NO: 17 or a fragment thereof having lipase activity;
b) a polypeptide having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 17 and having lipase activity; or
c) a polypeptide as set forth in SEQ ID NO: 17 except for one or several modifications (*i.e.* deletions, substitutions and/or insertions), such as 2, 3, 4, 5, 6, 7, 8, 9 amino acid modifications, or more amino acid modifications such as 10 and having lipase activity;
d) a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 23 or by a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;
e) a polypeptide having lipase activity encoded by a nucleic acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 23 or to a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;
f) a polypeptide having lipase activity encoded by a nucleic acid sequence which hybridizes under stringent conditions to the complement of the nucleic acid sequence of SEQ ID NO: 23; or
g) a polypeptide obtainable (preferably obtained) from *Streptomyces* (preferably *S. pristinaespiralis)* having lipase activity.

In a further aspect, the present invention provides a method of cleaning an item, comprising contacting the item with a composition comprising:

a) a polypeptide as shown in SEQ ID NO: 17 or a fragment thereof having lipase activity;
b) a polypeptide having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 17 and having lipase activity; or
c) a polypeptide as set forth in SEQ ID NO: 17 except for one or several modifications *(i.e.* deletions, substitutions and/or insertions), such as 2, 3, 4, 5, 6, 7, 8, 9 amino acid modifications, or more amino acid modifications such as 10 and having lipase activity;
d) a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 23 or by a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;
e) a polypeptide having lipase activity encoded by a nucleic acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 23 or to a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;
f) a polypeptide having lipase activity encoded by a nucleic acid sequence which hybridizes under stringent conditions to the complement of the nucleic acid sequence of SEQ ID NO: 23; or
g) a polypeptide obtainable (preferably obtained) from *Streptomyces* (preferably *S. pristinaespiralis)* having lipase activity.

Suitably, the item may be a clothing item or a tableware item.

The present invention provides many applications, methods and uses of a composition comprising a lipolytic enzyme and a hydrophobin. For the avoidance of doubt, each of these applications, methods and uses may be applied to a composition comprising:

a) a polypeptide as shown in SEQ ID NO: 17 or a fragment thereof having iipase activity;

b) a polypeptide having at ieast 70%, preferably at least 80%, preferably at least 85%, preferably at ieast 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at ieast 95%, preferably at ieast 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 17 and having lipase activity; or

c) a polypeptide as set forth in SEQ ID NO: 17 except for one or several modifications *(i.e.* deletions, substitutions and/or insertions), such as 2, 3, 4, 5, 6, 7, 8, 9 amino acid modifications, or more amino acid modifications such as 10 and having lipase activity;

d) a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 23 or by a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;

e) a polypeptide having lipase activity encoded by a nucleic acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at ieast 91%, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at ieast 95%, preferably at least 96%, preferably at least 97%, preferably at least 98%, or preferably at least 99% identity to the amino acid sequence shown as SEQ ID NO: 23 or to a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 23 by the degeneration of the genetic code;

f) a polypeptide having lipase activity encoded by a nucleic acid sequence which hybridizes under stringent conditions to the complement of the nucleic acid sequence of SEQ ID NO: 23; or

g) a polypeptide obtainable (preferably obtained) from *Streptomyces* (preferably *S. pristinaespiraiis)* having lipase activity.

HOST CELL

The term "host cell" - in relation to the present invention includes any cell that comprises either the nucleotide sequence or an expression vector as described above and which is used in the recombinant production of an enzyme having the specific properties as defined herein.

Thus, a further embodiment of the present invention provides host cells transformed or transfected with a nucleotide sequence that expresses the enzyme of the present invention. The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), funga!, yeast or plant cells.
5 Preferably, the host cells are not human cells.

Examples of suitable bacterial host organisms are gram positive or gram negative bacterial species.

10 Depending on the nature of the nucleotide sequence encoding the enzyme of the present invention, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or other fungi may be preferred. However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly *{e.g.,* hyper-glycosylation in yeast). In these instances, a
15 different fungal host organism should be selected.

The use of suitable host cells - such as yeast, fungal and plant host cells - may provide for post-translational modifications (e.g., myristoylation, glycosylation, truncation, lipidation and tyrosine, serine or threonine phosphorylation, or N-terminal
20 acetylation as may be needed to confer optimal biological activity on recombinant expression products of the present invention.

The host cell may be a protease deficient or protease minus strain.

25 The genotype of the host cell may be modified to improve expression.

Examples of host cell modifications include protease deficiency, supplementation of rare tRNAs, and modification of the reductive potential in the cytoplasm to enhance disulphide bond formation.

30

For example, the host cell *E. coli* may overexpress rare tRNAs to improve expression of heterologous proteins as exemplified/described in Kane *(Curr Opin Biotechnol* (1995), 6, 494-500 "Effects of rare codon clusters on high-level expression of heterologous proteins in *E. coli'). The* host cell may be deficient in a number of
35 reducing enzymes thus favouring formation of stable disulphide bonds as exemplified/described in Bessette *(Proc Natl Acad Sci USA* (1999), 96, 13703-13708

"Efficient folding of proteins with multiple disuiphide bonds in the *Escherichia cols* cytoplasm").

ISOLATED

In one aspect, the enzymes for use in the present invention may be in an isolated form.

The term "isolated" means that the sequence or protein is at least substantially free from at ieast one other component with which the sequence or protein is naturally associated in nature and as found in nature.

PURIFIED

In one aspect, the enzymes for use in the present invention may be used in a purified form.

The term "purified" means that the sequence is in a relatively pure state – *e.g.,* at least about 51% pure, or at least about 75%, or at least about 80%, or at least about 90% pure, or at least about 95% pure or at least about 98% pure.

CLONING A NUCLEOTIDE SEQUENCE ENCODING A POLYPEPTIDE ACCORDING TO THE PRESENT INVENTION

A nucleotide sequence encoding either a polypeptide which has the specific properties as defined herein or a polypeptide which is suitable for modification may be isolated from any cell or organism producing said polypeptide. Various methods are well known within the art for the isolation of nucleotide sequences.

For example, a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the polypeptide. If the amino acid sequence of the polypeptide is known, labelled oligonucleotide probes may be synthesised and used to identify polypeptide-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known

polypeptide gene could be used to identify polypeptide-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used.

Alternatively, polypeptide-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming enzyme-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing an enzyme inhibited by the polypeptide, thereby allowing clones expressing the polypeptide to be identified.

In a yet further alternative, the nucleotide sequence encoding the polypeptide may be prepared synthetically by established standard methods, *e.g.,* the phosphoroamidite method described by Beucage S.L. *et al.* (1981) *Tetrahedron Letters* 22, 1859-1869, or the method described by Matthes *et al.* (1984) *EMBO J.* 3, 801-805. In the phosphoroamidite method, oligonucleotides are synthesised, *e.g.,* in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.

The nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence. The DNA sequence may also be prepared by polymerase chain reaction (PGR) using specific primers, for instance as described in US 4,683,202 or in Saiki R K *et al.* *(Science* (1988) **239,** 487-491).

NUCLEOTIDE SEQUENCES

The present invention also encompasses nucleotide sequences encoding polypeptides having the specific properties as defined herein. The term "nucleotide sequence" as used herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or antisense strand.

The term "nucleotide sequence" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA for the coding sequence.

In a preferred embodiment, the nucleotide sequence *per* se encoding a polypeptide having the specific properties as defined herein does not cover the native nucleotide sequence in its natural environment when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall caii this preferred embodiment the "non-native nucleotide sequence". in this regard, the term "native nucleotide sequence" means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment.

However, the amino acid sequence encompassed by scope the present invention can be isolated and/or purified post expression of a nucleotide sequence in its native organism. Preferably, however, the amino acid sequence encompassed by scope of the present invention may be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism.

Preferably the polypeptide is not a native polypeptide. In this regard, the term "native polypeptide" means an entire polypeptide that is in its native environment and when it has been expressed by its native nucleotide sequence.

Typically, the nucleotide sequence encoding polypeptides having the specific properties as defined herein is prepared using recombinant DMA techniques *(i.e.,* recombinant DNA). However, in an alternative embodiment of the invention, the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers **MH** *et al.* (1980) *Nuc Acids Res Symp Ser* 2 15-23 and Horn T *et ai.* (1980) *Nuc Acids Res Symp Ser* 225-232).

MOLECULAR EVOLUTION

Once an enzyme-encoding nucleotide sequence has been isolated, or a putative enzyme-encoding nucleotide sequence has been identified, it may be desirable to modify the selected nucleotide sequence, for example it may be desirable to mutate the sequence in order to prepare an enzyme **in** accordance with the present invention.

Mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.

A suitable method is disclosed in Morinaga *et al. (Biotechnology* (1984) 2, 646-649).
5 Another method of introducing mutations into enzyme-encoding nucleotide sequences is described in Nelson and Long *(Analytical Biochemistry* (1989), 180, 147-151).

Instead of site directed mutagenesis, such as described above, one can introduce
10 mutations randomly for instance using a commercial kit such as the GeneMorph PGR mutagenesis kit from Stratagene, or the Diversify PGR random mutagenesis kit from Clontech. EP 0 583 265 refers to methods of optimising PGR based mutagenesis, which can also be combined with the use of mutagenic DNA analogues such as those described in EP 0 866 796. Error prone PGR technologies are suitable for the
15 production of variants of lipid acyl transferases with preferred characteristics. WO 02/06457 refers to molecular evolution of lipases.

A third method to obtain novel sequences is to fragment non-identical nucleotide sequences, either by using any number of restriction enzymes or an enzyme such as
20 Dnase I, and reassembling full nucleotide sequences coding for functional proteins. Alternatively one can use one or multiple non-identical nucleotide sequences and introduce mutations during the reassembly of the full nucleotide sequence. DNA shuffling and family shuffling technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics. Suitable methods for
25 performing 'shuffling' can be found in EP 0 752 008, EP 1 138 763, EP 1 103 606. Shuffling can also be combined with other forms of DNA mutagenesis as described in US 6,180,406 and WO 01/34835.

Thus, it is possible to produce numerous site directed or random mutations into a
30 nucleotide sequence, either *in vivo* or *in vitro,* and to subsequently screen for improved functionality of the encoded polypeptide by various means. Using *in silico* and exo-mediated recombination methods *(see, e.g.,* WO 00/58517, US 6,344,328, US 6,361 ,974), for example, molecular evolution can be performed where the variant produced retains very low homology to known enzymes or proteins. Such variants
35 thereby obtained may have significant structural analogy to known transferase enzymes, but have very low amino acid sequence homology.

As a **non-limiting** example, in addition, mutations or natural variants of a polynucleotide sequence can be recombined with either the wild type or other mutations or natural variants to produce new variants. Such new variants can also be screened for improved functionality of the encoded polypeptide.

5

The application of the above-mentioned and similar molecular evolution methods allows the identification and selection of variants of the enzymes of the present invention which have preferred characteristics without any prior knowledge of protein structure or function, and allows the production of non-predictable but beneficial
10 mutations or variants. There are numerous exampies of the application of molecular evolution in the art for the optimisation or alteration of enzyme activity, such examples include, but are not limited to one or more of the following: optimised expression and/or activity in a host ceil or in vitro, increased enzymatic activity, altered substrate and/or product specificity, increased or decreased enzymatic or
15 structural stability, altered enzymatic activity/specificity in preferred environmental conditions, *e.g.,* temperature, pH, substrate.

As will be apparent to a person skilled in the art, using molecular evolution tools an enzyme may be altered to improve the functionality of the enzyme.

20

Suitably, the nucleotide sequence encoding a lipolytic enzyme used in the invention may encode a variant, *i.e.,* the lipolytic enzyme may contain at least one amino acid substitution, deletion or addition, when compared to a parental enzyme. Variant enzymes retain at least **70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,**
25 99% homology with the parent enzyme.

Variant lipolytic enzymes may have decreased activity on triglycerides, and/or monoglycerides and/or diglycerides compared with the parent enzyme.

30 Suitably the variant enzyme may have no activity on triglycerides and/or monoglycerides and/or diglycerides.

Alternatively, the variant enzyme may have increased thermostability.

35 The variant enzyme may have increased activity on one or more of the following, polar lipids, phospholipids, lecithin, phosphatidylcholine, glycolipids, digalactosyl monoglyceride, monogalactosyl monoglyceride.

Variants of lipid acyltransferases are known, and one or more of such variants may be suitable for use in the methods and uses according to the present invention and/or in the enzyme compositions according to the present invention. By way of example only, variants of lipid acyltransferases are described in the following references may be used in accordance with the present invention: Hilton & Buckley *J. Biol. Chem.* 1991 Jan 15: 266 : 997-1000; Robertson *et al. J. Biol. Chem.* 1994 Jan 21; 269: 2146-50; Brumlik *et al. J. Bacteriol.* 1996 Apr; 178 : 2060-4; Peelman *et al. Protein Sci.* 1998 Mar; 7:587-99.

AMINO ACID SEQUENCES

The present invention also encompasses the use of amino acid sequences encoded by a nucleotide sequence which encodes an enzyme for use in any one of the methods and/or uses of the present invention.

As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and/or the term "protein". In some instances, the term "amino acid sequence" is synonymous with the term "peptide". In some instances, the term "amino acid sequence" is synonymous with "enzyme".

The amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques.

Suitably, the amino acid sequences may be obtained from the isolated polypeptides taught herein by standard techniques.

One suitable method for determining amino acid sequences from isolated polypeptides is as follows:

Purified polypeptide may be freeze-dried and 100 µg of the freeze-dried material may be dissolved in 50 µl of a mixture of 8 M urea and 0.4 M ammonium hydrogen carbonate, pH 8.4. The dissolved protein may be denatured and reduced for 15 minutes at 50°C following overlay with nitrogen and addition of 5 µl of 45 mM dithiothreitol. After cooling to room temperature, 5 µl of 100 mM iodoacetamide may be added for the cysteine residues to be derivatized for 15 minutes at room temperature in the dark under nitrogen.

135 μl of water and 5 μg of endoproteinase Lys-C in 5 μl of water may be added to the above reaction mixture and the digestion may be carried out at 37°C under nitrogen for 24 hours.

The resulting peptides may be separated by reverse phase HPLC on a VYDAC C18 column (0.46x1 5cm; 10μm; The Separation Group, California, USA) using solvent A: 0.1% TFA in water and solvent B: 0.1% TFA in acetonitrile. Selected peptides may be re-chromatographed on a Develosil C18 column using the same solvent system, prior to N-terminal sequencing. Sequencing may be done using an Applied Biosystems 476A sequencer using pulsed liquid fast cycles according to the manufacturer's instructions (Life Technologies, California, USA).

SEQUENCE IDENTITY OR SEQUENCE HOMOLOGY

Here, the term "homoiogue" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can be equated with "identity".

The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.

In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 50%, 55%, 60%, 70%, 71%, 72%, 73%, 74%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, preferably at least 95%, 96%, 97%, 98%, or 99% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (*i.e.,* amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

In the present context, a homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, preferably at least 95%, 96%, 97%, 98%, or 99% identical to a nucleotide sequence encoding a polypeptide of the present invention

(the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homoiogy can also be considered in terms of similarity (*i.e.,* amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can **calculate** % homology between two or more sequences.

% homology may be calculated over contiguous sequences, *i.e.,* one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it-fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons.

Calcination of maximum % homology therefore firstly requires the production of an optima! alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the Vector *NTI* (Invitrogen Corp.). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel *et al.* 1999 Short Protocols in Molecular Biology, 4th Ed - Chapter 18), and FASTA (Altschui *et al.* 1990 *J. Mol. Biol.* 403-410). Both BLAST and FASTA are available for offline and online searching (see Ausubel ef *al.* 1999, pages 7-58 to 7-60). However, for some applications, it is preferred to use the Vector NTI program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see *FEMS Microbiol* Lett 1999 174: 247-50; *FEMS Microbiol Lett* 1999 177: 187-8 and tatiana@ncbi.nlm.nih.gov).

Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. Vector NTI programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the default values for the Vector NTI ADVANCE™ 10 package.

Alternatively, percentage homologies may be calculated using the multiple alignment feature in Vector NTI ADVANCE™ 10 (Invitrogen Corp.), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), *Gene* 73, 237-244).

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

Suitably, the degree of identity with regard to a nucleotide sequence is determined over at least 20 contiguous nucleotides, preferably over at least 30 contiguous nucleotides, preferably over at least 40 contiguous nucleotides, preferably over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 100 contiguous nucleotides.

Suitably, the degree of identity with regard to a nucleotide sequence may be determined over the whole sequence.

5 Should Gap Penalties be used when determining sequence identity, then preferably the default parameters for the programme are used for pairwise alignment. For example, the following parameters are the current default parameters for pairwise alignment for BLAST 2:

FOR BLAST2	DNA	PROTEIN
EXPECT THRESHOLD	10	10
WORD SIZE	11	3
SCORING PARAMETERS		
Match/Mismatch Scores	2, -3	n/a
Matrix	n/a	BLOSUM62
Gap Costs	Existence: 5 Extension: 2	Existence: 11 Extension: 1

10 In one embodiment, preferably the sequence identity for the nucleotide sequences and/or amino acid sequences may be determined using BLAST2 (blastn) with the scoring parameters set as defined above.

For the purposes of the present invention, the degree of identity is based on the
15 number of sequence elements which are the same. The degree of identity in accordance with the present invention for amino acid sequences may be suitably determined by means of computer programs known in the art such as Vector NTI ADVANCE™ 11 (Invitrogen Corp.). For pairwise alignment the scoring parameters used are preferably BLOSUM62 with Gap existence penalty of 11 and Gap
20 extension penalty of 1.

Suitably, the degree of identity with regard to an amino acid sequence is determined over at least 20 contiguous amino acids, preferably over at least 30 contiguous amino acids, preferably over at least 40 contiguous amino acids, preferably over at
25 least 50 contiguous amino acids, preferably over at least 60 contiguous amino acids, preferably over at least 100 contiguous amino acids.

Suitably, the degree of identity with regard to an amino acid sequence may be determined over the whole sequence.

30

The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophi!icity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, giutamine, serine, threonine, phenylalanine, and tyrosine.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar – uncharged	C S T M
		N Q
	Polar – charged	D E
		K R
AROMATIC		H F W Y

The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur, *i.e.*, like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur, *i.e.*, from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyridylalanine, thienylalanine, naphthylalanine and phenylglycine.

Replacements may also be made by unnatural amino acids.

Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or β-alanine residues. A further form of variation, involves the presence of one or more amino acid residues in peptoid form, will be well understood by those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid residues wherein the α-carbon substituent group is on the residue's nitrogen atom rather than the a-carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon RJ *ei al., PNAS* (1992) 89, 9367-9371 and Horwel! DC, *Trends Biotechno!.* (1995) 13, 132-134.

Nucleotide sequences for use in the present invention or encoding a polypeptide having the specific properties defined herein may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of nucleotide sequences.

The present invention also encompasses the use of nucleotide sequences that are complementary to the sequences discussed herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other organisms etc.

Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other viral/bacterial, or cellular homologues particularly cellular homologues found in mammalian cells *(e.g.,* rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained

by probing **cDNA** libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences In the attached sequence listings under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic
5 variants of the polypeptide or nucleotide sequences of the invention.

Variants and strain/species homologues may also be obtained using degenerate PGR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the
10 present invention. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PiieUp program is widely used.

15 The primers used in degenerate PGR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

Alternatively, such polynucleotides may be obtained by site directed mutagenesis of
20 characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction polypeptide recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

25

Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, *e.g.,* a PGR primer, a primer for an alternative amplification reaction, a probe *e.g.,* labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers,
30 probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.

Polynucleotides such as DNA polynucleotides and probes according to the invention
35 may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using a PGR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g., of about 15 to 30 nucleotides) flanking a region of the lipid targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g., by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.

HYBRIDISATION

The present invention also encompasses the use of sequences that are complementary to the sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary thereto.

The term "hybridisation" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction (PGR) technologies.

The present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the subject sequences discussed herein, or any derivative, fragment or derivative thereof.

The present invention also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences discussed herein.

Hybridisation conditions are based on the melting temperature (Tm) of the nucleotide binding complex, as taught in Berger and Kimmei (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology. Vol 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.

5

Maximum stringency typically occurs at about Tm-5°C (5°C below the Tm of the probe); high stringency at about 5°C to 10°C below Tm; intermediate stringency at about 10°C to 20°C below Tm; and low stringency at about 20°C to 25°C below Tm. As will be understood by those of skill in the art, a maximum stringency hybridisation
10 can be used to identify or detect identical nucSeotide sequences while an intermediate (or low) stringency hybridisation can be used to identify or detect similar or related polynucleotide sequences.

Preferably, the present invention encompasses the use of sequences that are
15 complementary to sequences that are capable of hybridising under high stringency conditions or intermediate stringency conditions to nucleotide sequences encoding polypeptides having the specific properties as defined herein.

More preferably, the present invention encompasses the use of sequences that are
20 complementary to sequences that are capable of hybridising under high stringency conditions (e.g., 65°C and O.lxSSC {"IxSSC = 0.15 M NaCl, 0.015 M Na-citrate pH 7.0}) to nucleotide sequences encoding polypeptides having the specific properties as defined herein.

25 The present invention also relates to the use of nucleotide sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).

The present invention also relates to the use of nucleotide sequences that are
30 complementary to sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).

Also included within the scope of the present invention are the use of polynucleotide sequences that are capable of hybridising to the nucleotide sequences discussed
35 herein under conditions of intermediate to maximal stringency.

In a preferred aspect, the present invention covers the use of nucleotide sequences that can hybridise to the nucleotide sequences discussed herein, or the complement thereof, under stringent conditions {*e.g.,* 50°C and 0.2 x SSC).

5 In a more preferred aspect, the present invention covers the use of nucleotide sequences that can hybridise to the nucleotide sequences discussed herein, or the complement thereof, under high stringency conditions (e.g., 65°C and 0.1 x SSC).

BIOLOGICALLY ACTIVE

10

Preferably, the variant sequences etc. are at least as biologically active as the sequences presented herein.

As used herein "biologically active" refers to a sequence having a similar structural
15 function (but not necessarily to the same degree), and/or similar regulatory function (but not necessarily to the same degree), and/or similar biochemical function (but not necessarily to the same degree) of the naturally occurring sequence.

RECOMBINANT

20

In one aspect the sequence for use in the present invention is a recombinant sequence - *i.e.,* a sequence that has been prepared using recombinant DNA techniques.

25 These recombinant DNA techniques are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual,* Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press.

30 SYNTHETIC

In one aspect the sequence for use in the present invention is a synthetic sequence - *i.e.,* a sequence that has been prepared by *in vitro* chemical or enzymatic synthesis. It includes, but is not limited to, sequences made with optimal codon usage for host
35 organisms - such as the methylotrophic yeasts *Pichia* and *Hansenula.*

EXPRESSION OF POLYPEPTIDES

A nucleotide sequence for use in the present invention or for encoding a polypeptide having the specific properties as defined herein can be incorporated into a recombinant replicable vector. The vector may be used to replicate and express the nucleotide sequence, in polypeptide form, in and/or from a compatible host ceil. Expression may be controlled using control sequences which include promoters/enhancers and other expression regulation signals. Prokaryotic promoters and promoters functional in eukaryotic cells may be used. Tissue specific or stimuli specific promoters may be used. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.

The polypeptide produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellular^ depending on the sequence and/or the vector used. The coding sequences can be designed with signal sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane.

EXPRESSION VECTOR

The term "expression vector" means a construct capable of *in vivo* or *in vitro* expression.

Preferably, the expression vector is incorporated into the genome of a suitable host organism. The term "incorporated" preferably covers stable incorporation into the genome.

The nucleotide sequence encoding an enzyme for use in the present invention may be present in a vector in which the nucleotide sequence is operably linked to regulatory sequences capable of providing for the expression of the nucleotide sequence by a suitable host organism.

The vectors for use in the present invention may be transformed into a suitable host cell as described below to provide for expression of a polypeptide of the present invention.

The choice of vector *e.g.,* a plasmid, cosmid, or phage vector will often depend on the host cell into which it is to be introduced.

5 The vectors for use in the present invention may contain one or more selectable marker genes such as a gene which confers antibiotic resistance *e.g.,* ampiciilin, kanamycin, chloramphenicol or tetracycline resistance. Alternatively, the selection may be accomplished by co-transformation (as described in WO 91/17243).

10 Vectors may be used *in vitro,* for example for the production of RNA or used to transfect, transform, transduce or infect a host ceil.

The vector may further comprise a nucleotide sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of
15 replication of plasmids pUC1 9, pACYCI 77, pUB1 10, pE1 94, pAMB1 and plJ702.

REGULATORY SEQUENCES

In some applications, the nucleotide sequence for use in the present invention is
20 operably linked to a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by the chosen host cell. By way of example, the present invention covers a vector comprising the nucleotide sequence of the present invention operably linked to such a regulatory sequence, *i.e.,* the vector is an expression vector.

25

The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible
30 with the control sequences.

The term "regulatory sequences" includes promoters and enhancers and other expression regulation signals.

35 The term "promoter" is used in the normal sense of the art, *e.g.* an RNA polymerase binding site.

Enhanced expression of the nucleotide sequence encoding the enzyme of the present invention may also be achieved by the selection of heterologous regulatory regions, e.g., promoter, secretion leader and terminator regions.

5

Preferably, the nucleotide sequence according to the present invention is operably linked to at least a promoter.

Examples of suitable promoters for directing the transcription of the nucleotide
10 sequence in a bacterial, fungal or yeast host are well known in the art.

CONSTRUCTS

The term "construct" - which is synonymous with terms such as "conjugate",
15 "cassette" and "hybrid" - includes a nucleotide sequence encoding a polypeptide having the specific properties as defined herein for use according to the present invention directly or indirectly attached to a promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the
20 nucleotide sequence of the present invention. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In some cases, the terms do not cover the natural combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment.

25

The construct may even contain or express a marker which allows for the selection of the genetic construct.

For some applications, preferably the construct comprises at least a nucleotide
30 sequence of the present invention or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein operably linked to a promoter.

ORGANISM

35 The term "organism" in relation to the present invention includes any organism that could comprise a nucleotide sequence according to the present invention or a

nucleotide sequence encoding for a polypeptide having the specific properties as defined herein and/or products obtained therefrom.

The term "transgenic organism" in relation to the present invention includes any organism that comprises a nucleotide sequence coding for a polypeptide having the specific properties as defined herein and/or the products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence coding for a polypeptide having the specific properties as defined herein within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.

Suitable organisms include a prokaryote, fungus yeast or a plant.

The term "transgenic organism" does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.

Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, a nucleotide sequence coding for a polypeptide having the specific properties as defined herein, constructs as defined herein, vectors as defined herein, plasmids as defined herein, cells as defined herein, or the products thereof. For example the transgenic organism can also comprise a nucleotide sequence coding for a polypeptide having the specific properties as defined herein under the control of a promoter not associated with a sequence encoding a lipid acyltransferase in nature.

TRANSFORMATION OF HOST CELLS/ORGANISM

The host organism can be a prokaryotic or a eukaryotic organism.

Examples of suitable prokaryotic hosts include bacteria such as *E. coli* and *Bacillus licheniformis,* preferably *B. licheniformis.*

Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook *et al.* (Molecular Cloning: A Laboratory Manual, 2nd

edition, 1989, Cold Spring Harbor Laboratory Press). If a prokaryotic host is used then the nucleotide sequence may need to be suitabiy modified before transformation - such as by remova! of introns.

5 !n another embodiment the transgenic organism can be a yeast.

Filamentous fungi ceiis may be transformed using various methods known in the art - such as a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known. The use of
10 *Aspergillus* as a host microorganism is described in EP 0 238 023. In one embodiment, preferably *T. reesei* is the host organism.

Another host organism can be a plant. A review of the general techniques used for transforming plants may be found in articles by Potrykus *{Annu Rev Plant Physiol*
15 *Plant Mol Biol* (1991) 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). Further teachings on plant transformation may be found in EP-A-0449375.

General teachings on the transformation of fungi, yeasts and plants are presented in
20 following sections.

TRANSFORMED FUNGUS

A host organism may be a fungus - such as a filamentous fungus. Examples of
25 suitable such hosts include any member belonging to the genera *Fusarium, Thermomyces, Acremonium, Aspergillus, Penicillium, Mucor, Neurospora, Trichoderma* and the like. In one embodiment, *Trichoderma* is the host organism, preferably *T. reesei.*

30 Teachings on transforming filamentous fungi are reviewed in US-A-5741665 which states that standard techniques for transformation of filamentous fungi and culturing the fungi are well known in the art. An extensive review of techniques as applied to *N. crassa* is found, for example in Davis and de Serres, *Methods Enzymol* (1971) **17A:** 79-143.

35

Further teachings on transforming filamentous fungi are reviewed in US-A-5674707.

In one aspect, the host organism can be of the genus *Aspergillus,* such as *Aspergillus niger.*

A transgenic *Aspergillus* according to the present invention can also be prepared by following, for example, the teachings of Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli S.D., Kinghorn J.R.(Editors) *Aspergillus:* 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666).

Gene expression in filamentous fungi has been reviewed in Punt *et al. Trends Bioiechnol.* (2002); 20(5):200-6, Archer & Peberdy *Crit. Rev. Biotechnoi.* (1997) *17*:273-306.

TRANSFORMED YEAST

In another embodiment, the transgenic organism can be a yeast.

A review of the principles of heterologous gene expression in yeast are provided in, for example, *Methods Mol Biol* (1995), **49**:341-54, and *Curr Opin Biotechnoi* (1997); 8:554-60.

In this regard, yeast - such as the species *Saccharomyces cerevisi or Pichia pastoris* or *Hansenula polymorpha* (see FEMS *Microbiol Rev* (2000 24:45-66), may be used as a vehicle for heterologous gene expression.

A review of the principles of heterologous gene expression in *Saccharomyces cerevisiae* and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", *Yeasts,* Vol **5**, Anthony H Rose and J. Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

For the transformation of yeast, several transformation protocols have been developed. For example, a transgenic *Saccharomyces* according to the present invention can be prepared by following the teachings of Hinnen *et al.,* (1978, *Proceedings of the National Academy of Sciences of the USA* **75,** 1929); Beggs, J D (1978, *Nature,* London, **275,** 104); and Ito, H *et al.* (1983, *J Bacteriology* **153,** 163-168).

The transformed yeast cells may be selected using various selective markers - such as auxotrophic markers dominant antibiotic resistance markers.

A suitable yeast host organism can be selected from the biotechnologicaliy relevant yeasts species such as, but not limited to, yeast species selected from *Pichia* spp., *Hansenuia* spp., *Kluyveromyces, Yarrowinia* spp., *Saccharomyces* spp., including S. *cerevisiae,* or *Schizosaccharomyce* spp., including *Schizosaccharomyce pombe.*

A strain of the methylotrophic yeast species *Pichia pastoris* may be used as the host organism.

In one embodiment, the host organism may be a *Hansenuia* species, such as *H. polymorpha* (as described in WO 01/39544).

TRANSFORMED PLANTS/PLANT CELLS

A host organism suitable for the present invention may be a plant. A review of the general techniques may be found in articles by Potrykus *(Annu Rev Plant Physiol Plant Mol Biol* (1991) 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27), or in WO 01/16308. The transgenic plant may produce enhanced levels of phytosterol esters and phytostanol esters, for example.

CULTURING AND PRODUCTION

Host cells transformed with the nucleotide sequence of the present invention may be cultured under conditions conducive to the production of the encoded enzyme and which facilitate recovery of the enzyme from the cells and/or culture medium.

The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in questions and obtaining expression of the enzyme.

The protein produced by a recombinant cell may be displayed on the surface of the cell.

The enzyme may be secreted from the host cells and may conveniently be recovered from the culture medium using well-known procedures.

SECRETION

Often, it is desirable for the polypeptide to be secreted from the expression host into the culture medium from where the enzyme may be more easily recovered. According to the present invention, the secretion leader sequence may be selected on the basis of the desired expression host. Hybrid signal sequences may also be used with the context of the present invention.

Typical examples of secretion leader sequences not associated with a nucleotide sequence encoding a lipid acyltransferase in nature are those originating from the fungal amyloglucosidase (AG) gene (g/aA - both 18 and 24 amino acid versions *e.g.,* from *Aspergillus),* the a-factor gene (yeasts *e.g., Saccharomyces, Kluyveromyces* and *Hansenula)* or the a-amylase gene *(Bacillus).*

DETECTION

A variety of protocols for detecting and measuring the expression of the amino acid sequence are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (R!A) and fluorescent activated cell sorting (FACS).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic and amino acid assays.

A number of companies such as Pharmacia Biotech (Piscataway, NJ, USA), Promega (Madison, WI, USA), and US Biochemical Corp (Cleveland, OH, USA) supply commercial kits and protocols for these procedures.

Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US-A-3,81 7,837; US-A-3,850,752; US-A-3,939,350; US-A-3,996,345; US-A-4,277,437; US-A-4,275,149 and US-A-4,366,241 .

Also, recombinant immunoglobulins may be produced as shown in US-A-4,816,567.

FUSION PROTEINS

An enzyme for use in the present invention may be produced as a fusion protein, for example to aid in extraction and purification thereof. Examples of fusion protein partners include giutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β-galactosidase. it may aiso be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removai of fusion protein sequences. Preferably the fusion protein will not hinder the activity of the protein sequence,

Gene fusion expression systems in *E. coli* have been reviewed in *Curr. Opin. Biotechnol.* (1995) 6:501-6.

The amino acid sequence of a poiypeptide having the specific properties as defined herein may be iigated to a non-native sequence to encode a fusion protein. For example, for screening of peptide libraries for agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a non-native epitope that is recognised by a commercially available antibody.

ADDITIONAL POIs

The sequences for use according to the present invention may also be used in conjunction with one or more additional proteins of interest (POIs) or nucleotide sequences of interest (NOIs).

Non-limiting examples of POIs include: proteins or enzymes involved in starch metabolism, proteins or enzymes involved in glycogen metabolism, acetyl esterases, aminopeptidases, amylases, arabinases, arabinofuranosidases, carboxypeptidases, catalases, cellulases, chitinases, chymosin, cutinase, deoxyribonucleases, epimerases, esterases, a-galactosidases, β-galactosidases, a-glucanases, glucan lysases, endo-(3-glucanases, glucoamylases, glucose oxidases, u-glucosidases, β-glucosidases, glucuronidases, herricellulases, hexose oxidases, hydrolases, invertases, isomerases, laccases, lipases, lyases, mannosidases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectin depolymerases, pectin methyl esterases, pectinolytic enzymes, peroxidases, phenoloxidases, phytases, polygalacturonases, proteases, rhamno-galacturonases, ribonucleases, thaumatin, transferases, transport proteins, transglutaminases, xylanases, hexose

oxidase (D-hexose: O_2-oxidoreductase, EC 1.1 .3.5) or combinations thereof. The NOI may even be an antisense sequence for any of those sequences.

The POI may even be a fusion protein, for example to aid in extraction and
5 purification.

The POI may even be fused to a secretion sequence.

DETERGENT

10

The compositions of the present invention may form a component of a cleaning and/or detergent composition. In particular, certain embodiments of the present invention may additionally include a detergent.

15 In general, cleaning and detergent compositions are well described in the art and reference is made to WO 96/34946; WO 97/07202; and WO 95/30011 for further description of suitable cleaning and detergent compositions.

The compounds of the invention may for example be formulated as a hand or
20 machine laundry detergent composition, including a laundry additive composition suitable for pretreatment of stained fabrics, and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations (including car washing or cleaning compositions), or be formulated for hand or machine dishwashing operations. It may
25 also be formulated for use as a personal hygiene product, including but not limited to hand soaps, shampoos and shower gels.

In one embodiment the laundry composition of the present invention may comprise the lipolytic enzyme, hydrophobin and, optionally, detergent in combination with one
30 or more enzymes, such as a protease, a carboxypeptidase, an aminopeptidase, an amylase, a glucoamylase, a maltogenic amylase, a non-maltogenic amylase, an α-galactosidase, a β-galactosidase, an a-glucosidase, a β-glucosidase, a phospholipase, a glycosyltransferase, a chitinase, a cutinase, a carbohydrase, a cellulase, a pectinase, a mannanase, a mannosidase, an arabinase, a galactanase, a
35 xylanase, an oxidase, a polyesterase, a laccase, a cyclodextrin esterase, a phytase, a catalase, a haloperoxidase, and/or a peroxidase, a pectinolytic enzyme, a

peptidogiutaminase, a poiyphenoloxidase, a transglutaminase, a deoxyribonuciease, a ribonuciease, and/or combinations thereof. in genera! the properties of the chosen enzyrne(s) should be compatible with the selected detergent, (e.g., phi-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the
5 enzyrne(s) should be present in effective amounts.

Proteases: suitable proteases include those of animal, vegetable or microbial origin. Chemically modified or protein engineered mutants are also suitable. The protease may be a serine protease or a metalloprotease, *e.g.,* an alkaline microbial protease
10 or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from *Bacillus* sp., e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309 *(see. e.g.,* U.S. Patent No. 6,287,841), subtilisin 147, and subtilisin 168 *(see, e.g.,* WO 89/06279). Examples of trypsin-like proteases are trypsin *(e.g.,* of porcine or bovine origin), and *Fusarium* proteases *(see, e.g.,* WO 89/06270 and WO 94/25583).
15 Examples of useful proteases also include but are not limited to the variants described in WO 92/1 9729 and WO 98/201 15. Suitable commercially available protease enzymes include ALCALASE®, SAVINASE®, LIQUANASE®, OVOZYME®, POLARZYME®, ESPERASE®, EVERLASE®, and KANNASE® (Novozymes, formerly Novo Nordisk A/S); EXCELLASE™, MAXATASE®, MAXACAL™,
20 MAXAPEM ™, PROPERASE®, PROPERASE L®, PURAFECT®, PURAFECT L®, PURAFAST™ , OXP ™, FN2 ™, and FN3 ™ (Genencor - a division of Danisco A/S).

Polyesterases: Suitable polyesterases include, but are not limited to, those described in WO 01/34899 (Genencor) and WO 01/14629 (Genencor), and can be included in
25 any combination with other enzymes discussed herein.

Amylases: The compositions can comprise amylases such as a-amylases (EC 3.2.1.1), G4-forming amylases (EC 3.2.1.60), β-amylases (EC 3.2.1.2) and γ-amylases (EC 3.2.1.3). These can include amylases of bacterial or fungal origin,
30 chemically modified or protein engineered mutants are included. Commercially available amylases, such as, but not limited to, DURAMYL®, TERMAMYL ™, FUNGAMYL® and BAN ™ (Novozymes, formerly Novo Nordisk A/S), RAPIDASE®, and PURASTAR® (Danisco USA, Inc.), LIQUEZYME ™, NATALASE ™, SUPRAMYL ™, STAINZYME ™, FUNGAMYL and BAN ™ (Novozymes A/S),
35 RAPIDASE ™, PURASTAR™ , PURASTAROXAM ™ and POWERASE ™ (from

Danisco USA Inc.), GRINDAMYL™ PowerFresh, POWERFlex™ and GRINDAMYL PowerSoft (from Danisco A/S).

Peroxidases/Oxidases: Suitable peroxidases/oxidases contemplated for use in the compositions include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from *Coprinus, e.g.,* from *C. cinereus,* and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257. Commercially available peroxidases include GUARDZYME® (Novozymes A/S).

Cellulases: Suitable cellulases include those of bacteria! or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, e.g.,* the fungal cellulases produced from *Humicola insolens, Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in U.S. Patent Nos. 4,435,307; 5,648,263; 5,691 ,178; 5,776,757; and WO 89/09259, for example. Exemplary cellulases contemplated for use are those having colour care benefit for the textile. Examples of such cellulases are cellulases described in EP 0495257; EP531372; WO 99/25846 (Genencor International, Inc.), WO 96/34108 (Genencor International, Inc.), WO 96/1 1262; WO 96/29397; and WO 98/08940, for example. Other examples are cellulase variants, such as those described in WO 94/07998; WO 98/12307; WO 95/24471 ; WO 99/01544; EP 531 315; U.S. Patent Nos. 5,457,046; 5,686,593; and 5,763,254. Commercially available cellulases include CELLUZYME®, CAREZYME® and ENDOLASE® (Novozymes, formerly Novo Nordisk A/S); CLAZINASE™ and PURADAX® HA (Genencor); and KAC-50Q(B)™ (Kao Corporation).

Examples of commercially available mannanases include MANNAWAY™ (Novozymes, Denmark) and MANNASTAR™ (Genencor).

The composition of the invention can be formulated as either a solid or a liquid. Examples of formulations include granulates, pellets, slurries, bars, pastes, foams, gels, strips, etc. Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries. A liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or non-aqueous.

Non-dusting granulates may be produced, e. g., as disclosed in US 4,106,991 and 4,661 ,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly (ethylene oxide) products (polyethylene glycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nony!phenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono-and di-and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591 . Liquid enzyme preparations may, for instance, be stabilized by adding a polyo! such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP-A-238216.

The detergent composition may also comprise one or more further surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight.

When included therein the detergent will usually contain from about 1% to about 40% of an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl-or alkenylsuccinic acid or soap.

When included therein the detergent will usually contain from about 0.2% to about 40% of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylste, alkylpolyglycoside, alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or other N-acyl or N-alkyl derivatives of glucosamine.

The detergent may contain 0-65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl-or alkenylsuccinic acid, soluble silicates or layered silicates (e. g. SKS-6 from Hoechst).

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose, poly (vinylpyrrolidone), poly (ethylene glycol), poly (vinyl alcohol), poly (vinylpyridine-N-oxide), poly (vinylimidazole), po!ycarboxylates such as

polyacryiates, maleic/acry!ic acid copolymers and iauryl methacrylate / acrylic acid copolymers.

The detergent may contain a bleaching system which may comprise a hydrogen peroxide source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetylethyienediamine or nonanoyioxybenzenesulfonate. Alternatively, the bleaching system may comprise peroxyacids of e.g., the amide, imide, or sulfone type.

The enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e. g., a polyo! such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e. g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in *e.g.,* WO 92/1 9709 and WO 92/1 9708.

The detergent may also contain other conventional detergent ingredients such as fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.

DOSAGE

In the compositions of the present invention, the hydrophobin may be present in any concentration sufficient to enable it to exhibit the effects described herein. Suitably, the hydrophobin is present in a concentration of between 0.001% and 5%, preferably 0.002% to 2.5%, more preferably 0.005% to 1%, even more preferably 0.01% to 0.5% by weight of the total weight of the composition. In particularly preferred examples, the hydrophobin is present in a concentration of 0.01 , 0.05, 0.1 , 0.25 or 0.4% by weight of the total weight of the composition.

In the compositions of the present invention, the lipolytic enzyme may be present in any concentration sufficient to enable it to exhibit the effects described herein.

Suitably, the lipolytic enzyme is present in a concentration of 0.001 to 400 ppm, preferably 0.002 to 200 ppm, more preferably 0.005 to 100 ppm, even more

preferably 0.01 to 50 ppm, still more preferably 0.02 to 25 pprn, of pure enzyme protein by weight of the total weight of the composition.

Suitably, the lipolytic enzyme is present in a concentration of 0.025 to 25, preferably 0.05 to 10, more preferably 0.1 to 5, units of enzyme activity per g of the composition. The activity is measured according to the trioctanoate assay described below, wherein 1 unit of activity represents 1 µmol of the free fatty acid produced by 1 g of enzyme solution in 1 minute.

Where the compositions of the present invention include a detergent, the detergent may be present in any concentration sufficient to enable it to exhibit the effects described herein. Suitably, the detergent is present in a concentration of between 0.001 and 20 g/L, preferably 0.01 to 10 g/L, more preferably 0.05 to 5 g/L, even more preferably 0.1 to 2 5 g/L by Do the litres refer to the volume of the washing solution!n particularly preferred examples, the detergent is present in a concentration of 0.01 , 0.05, 0.1, 0.25 or 0.4 g/L of the washing solution.

Trioctanoate assay

Reaction emulsions of trioctanoate in the compositions was prepared from 0.4% trioctanoate pre-suspended in ethanol (5%), in one of two buffers: 0.05M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) adjusted to pH 8.2, or 0.05M N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) adjusted to pH 10. For both buffers water hardness adjusted to 240 ppm. The final assay mixtures contained varying amounts of detergents, to aid in the emulsification of the triglyceride.

The reaction emulsions were made by applying high shear mixing for 2 minutes (24000 m^{-1}, Ultra Turrax T25, Janke & Kunkel), and then transferring 150 pL to 96-well microtiter plate wells already containing 30 µL enzyme samples. Free fatty acid generation was measured using an *in vitro* enzymatic colorimetric assay for the quantitative determination of non-esterified fatty acids (NEFA). This method is specific for free fatty acids, and relies upon the acylation of coenzyme A (CoA) by the fatty acids in the presence of added acyl-CoA synthetase. The acyl-CoA thus produced is oxidized by added acy!-CoA oxidase with generation of hydrogen peroxide, in the presence of peroxidase. This permits the oxidative condensation of 3-methyl -N-ethyl -N(P-hydroxyethyl)-aniline with 4-aminoantipyrine to form a purple colored adduct which can be measured colorimetrically. The amount of free fatty

acids generated after a 6 minute incubation at 30°C was determined using the materials in a NEFA HR(2) kit (Wako Chemicals GmbH, Germany) by transferring 30 µL of the hydrolysis solution to 96-well microtiter plate wells already containing 120 pL NEFA A solution. Incubation for 3 min at 30°C was followed by addition of 60 µL NEFA B solution. After incubation for 4.5 min at 30°C OD at 520 nm was measured.

LAUNDRY COMPOSITIONS

The hydrophobins used in the present invention may be generated *in situ* in a laundry composition, for example by hydrolysis of hydrophobin precursor (such as a hydrophobin fusion protein) in the laundry composition.

The hydrophobin precursor (such as a hydrophobin fusion protein) is required in order to generate *in situ* the hydrophobins used in the present invention. It may be present as an initial component of the laundry composition. Alternatively, if no or insufficient hydrophobin precursor is initially present, this component can be added to the composition.

If required, a catalyst (particularly an enzyme, especially a protease enzyme) may be present. It may be present as an initial component of the laundry composition. Alternatively, if no or insufficient catalyst is initially present, this component can be added to the composition.

The laundry composition may further comprise a stain, which may be a lipid (in particular, a triglyceride and/or a diglyceride and/or a monoglyceride). The stain may be on a surface, for example a fabric. The laundry composition of the present invention may therefore comprise a surface for example a fabric.

Converting a hydrophobin precursor into a hydrophobin used in the present invention may help remove a stain comprising a lipid from a fabric.

CLEANING METHODS

The present invention further comprises a method of removing a lipid-based stain from a surface by contacting the surface with a composition according to the invention. In addition, the present invention comprises a method of cleaning a

surface, comprising contacting the surface with a composition according to the invention. Furthermore, the present invention comprises a method of cleaning an item (particularly although not exclusively a clothing item or a tableware item), comprising contacting the item with a composition according to the invention.

In another aspect, methods for removing oily stains from fabrics are provided. The methods generally involve identifying fabrics having oily stains, contacting the fabrics with a composition of the invention, and rinsing the fabric to remove the oily stain from the fabrics.

In some embodiments, the lipolytic enzyme, the hydrophobin and, optionally, the detergent are present together in a single composition. In some embodiments, the lipolytic enzyme, the hydrophobin and, optionally, the detergent are separate in different compositions that are combined prior to contacting the fabric, or mixed together on the fabric. Therefore, application of the lipase and the adjuvant may be simultaneous of sequential. In some embodiments, the contacting occurs in a wash pretreatment step, *i.e.,* prior to hand or machine-washing a fabric. In some embodiments, the contacting occurs at the time of hand or machine-washing the fabric. The contacting may occur as a result of mixing the present compositions with wash water, spraying, pouring, or dripping the composition on the fabric, or applying the composition using an applicator.

The methods are effective for removing a variety of oil stains, or portions of oily stains, which typically include esters of fatty acids, such as triglycerides.

It will be appreciated that rinsing may occur some time after the washing, and that in some aspects the present method of cleaning is essentially complete following the contacting of the fabric with the composition.

FOODSTUFF

The compositions of the present invention may be used as a component of a foodstuff. The term "foodstuff' as used herein means a substance which is suitable for human and/or animal consumption.

Suitably, the term "foodstuff' as used herein may mean a foodstuff in a form which is ready for consumption. Alternatively or in addition, however, the term foodstuff as

used herein may mean one or more food materials which are used in the preparation of a foodstuff. By way of example only, the term foodstuff encompasses both baked goods produced from dough as well as the dough used in the preparation of said baked goods.

The foodstuff may be in the form of a solution or as a solid - depending on the use and/or the mode of application and/or the mode of administration.

When used as - or in the preparation of - a food – such as functional food - the composition of the present invention may be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant, a nutritionally active ingredient.

In a preferred aspect the present invention provides a foodstuff as defined above wherein the foodstuff is selected from one or more of the following: eggs, egg-based products, including but not limited to mayonnaise, salad dressings, sauces, ice creams, egg powder, modified egg yolk and products made therefrom; baked goods, including breads, cakes, sweet dough products, laminated doughs, liquid batters, muffins, doughnuts, biscuits, crackers and cookies; confectionery, including chocolate, candies, caramels, halawa, gums, including sugar free and sugar sweetened gums, bubble gum, soft bubble gum, chewing gum and puddings; frozen products including sorbets, preferably frozen dairy products, including ice cream and ice milk; dairy products, including cheese, butter, milk, coffee cream, whipped cream, custard cream, milk drinks and yoghurts; mousses, whipped vegetable creams, meat products, including processed meat products; edible oils and fats, aerated and non-aerated whipped products, oil-in-water emulsions, water-in-oil emulsions, margarine, shortening and spreads including low fat and very low fat spreads; dressings, mayonnaise, dips, cream based sauces, cream based soups, beverages, spice emulsions and sauces.

Suitably the foodstuff in accordance with the present invention may be a "fine food", including cakes, pastry, confectionery, chocolates, fudge and the like.

In one aspect the foodstuff in accordance with the present invention may be a dough product or a baked product, such as bread, a fried product, a snack, cakes, pies,

brownies, cookies, noodies, snack items such as crackers, graham crackers, pretzels, and potato chips, and pasta.

in another aspect the foodstuff in accordance with the present invention may be a
5 convenience food, such as a part-baked or part-cooked product. Examples of such part-baked or part-cooked product include part-baked versions of the dough and baked products described above.

in a further aspect, the foodstuff in accordance with the present invention may be a
10 plant derived food product such as flours, pre-mixes, oils, fats, cocoa butter, coffee whitener, salad dressings, margarine, spreads, peanut butter, shortenings, ice cream, cooking oils.

In another aspect, the foodstuff in accordance with the present invention may be a
15 dairy product, including butter, milk, cream, cheese such as natural, processed, and imitation cheeses in a variety of forms (including shredded, block, slices or grated), cream cheese, ice cream, frozen desserts, yoghurt, yoghurt drinks, butter fat, anhydrous milk fat, other dairy products. The enzyme according to the present invention may improve fat stability in dairy products.

20

In another aspect, the foodstuff in accordance with the present invention may be a food product containing animal derived ingredients, such as processed meat products, cooking oils, shortenings.

25 In a further aspect, the foodstuff in accordance with the present invention may be a beverage, a fruit, mixed fruit, a vegetable, a marinade or wine.

In one aspect, the foodstuff in accordance with the present invention is a plant derived oil (*i.e.* a vegetable oil), such as olive oil, sunflower oil, peanut oil or
30 rapeseed oil. The oil may be a degummed oil.

EXAMPLES

EXAMPLE 1

5

The following experiments were carried out to test whether the cleaning performance of a lipase is enhanced by adding hydrophobin in the presence or absence of commercially available heat inactivated detergent.

10 The lipases used were as follows (each dosed in a single dose): -
LIPEX™ (abH23.1 , fungal) (SEQ ID NO: 11) (commercially available from Novozymes A/S), 1.25 mg in 1 mL
LIPOMAX™ (abH15.2, family 1-1) (SEQ ID NO: 15) (commercially available from Danisco A/S), 6 mg in 1 mL
15 SprLip2 (abH16, family I-7) (SEQ ID NO: 17), 258 µL in 1 mL
TfuLip2 (abH25.1 , family III) (SEQ ID NO: 16), 30.8 pL in 1 mL

The hydrophobin used was hydrophobin HFBII (SEQ ID NO: 2; obtainable from the fungus *Trichoderma reesei).* 26.6 g HFBII (containing 150 mg/g hydrophobin protein)
20 was dissolved in 100 mL water to give a solution containing 40 g/L hydrophobin protein. The solution was diluted as appropriate to give a hydrophobin dose of 0.01, 0.05, 0.1 , 0.25 and 0.40% by weight of the total weight of the composition.

The detergents used were heat inactivated liquid detergent (ARIEL™ colour liquid)
25 and heat inactivated powder detergent (ARIEL™ colour powder). These are commercially available from Procter & Gamble. The detergents were diluted as appropriate to give a dose of 0, 0.1 , 0.25 and 0.4 g/L.

The detergents were heat-inactivated as follows: the liquid detergents were placed in
30 a water bath at 95°C for 2 hours, while 0.1 g/mL preparations in water of the powder detergents were boiled on a hot plate for 1 hour. Heat treatments inactivate the enzymatic activity of any protein components in commercial detergent formulas, while retaining the properties of the nonenzymatic detergent components. Following heating, the detergents are diluted and assayed for lipase enzyme activity.

35

Cleaning performance of lipase and hydrophobin on stained fabrics was tested in a microswatch assay format. Stain removal experiments were carried out using a lipid-

containing technical stain (CS-61 swatches: cotton, beef fat with colorant, purchased from Center for Testmaterials, Netherlands) set in a 24-well plate format (Nunc, Denmark). Each assay well was set to contain a pre-cut 13 mm piece of CS-61 swatch. Swatches were pre-read using a scanner (Microtek Scan Maker 900) and placed in the 24-well plate.

The buffers used were 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (0.2M, pH 8.2) for testing liquid detergents, and 20 mM N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) (0.2M, pH 10.0) for testing powder detergents. Wafer hardness was adjusted to 24 degrees French (FH - one degree French is defined as 10 milligrams of calcium carbonate per litre of water) using 15000 ppm 2/1 Ca^{2+}/Mg^{2+} diluted to 2400 ppm (dilution factor 6.25) for both buffers.

A 24 well plate was used, each well containing 1 ml solution. The hydrophobin concentration in each row was as follows: zero; 0.01%; 0.05%; 0.1%; 0.25%; and 0.4% by weight of the total weight of the composition. The detergent concentration in each column was as follows: zero; 0.1 g/L; 0.25 g/L; and 0.4 g/L.

900 μL of the appropriate buffer described above was added to each swatch-containing well of the 24-well plate. 100 μL hydrophobin solution was added into each well. To initiate the reaction, enzyme samples were added at a volume of 100 μL into each well. The plates were shaken for 30 minutes at 200 rpm at 37°C. After incubation, the reaction buffer was removed and the fabric in each well was rinsed with 1 mL distilled water three times. After removing the rinse the swatches were dried at 50°C for 4 hours and reflectance was measured. Cleaning performance was quantified after a single wash cycle. Stain removal was calculated as the difference of the post- and pre-cleaning RGB colour measurements for each swatch. RGB measurements were taken with a scanner (Microtek Scan Maker 900).

The difference in Stain Removal Index (ΔSRI) values of the washed fabric were calculated in relation to the unwashed fabrics using the formula:

% Soil Removal$_{(RGB)}$ = (Soil removal $\Delta E_{(RGB)}$/ Initial soil $\Delta E_{(RGB)}$) x 100%

Where:

Soil removal $\Delta E_{(RGB)} = \sqrt{\left((R_{after} - R_{before})^2 + (G_{after} - G_{before})^2 + (B_{after} - B_{before})^2\right)}$

And:

Initial soil $\Delta E_{(RGB)} = \sqrt{((R_{ref} - R_{before})^2 + (G_{ref} - G_{before})^2 + (B_{ref} - B_{before})^2)}$

RGB_{ref} values are the values of the unsoiled cotton (white).

The results are shown in Figures (Figs). 1a through 5e, as follows:

Figs. 1a through 1c: no lipolytic enzyme (control)
Figs. 2a through 2e: the lipolytic enzyme LIPEX™ (abH23.1)
Figs. 3a through 3e: the lipolytic enzyme LIPOMAX™ (abH15.2)
Figs. 4a through 4e: the lipolytic enzyme SprLip2 (abH16)
Figs. 5a through 5e: the lipolytic enzyme TfuLip2 (abK25.1)

In particular, Figs. 2e, 4e and 5e illustrate the effects of hydrophobin on the presence of lipases in the system in the absence of a detergent. These Figures show that, for these lipases at least, a synergistic effect superior to the additive effect of each component when used individually can be observed.

In addition, Figure 2b illustrates that, when a combination of hydrophobin, the lipase LIPEX® and the detergent ARIEL® Color Liquid is used, as the concentration of the detergent increases, the system reaches a performance plateau at lower concentrations of hydrophobin (0.05% instead of 0.4%) compared with when no detergent is used. Furthermore, Figure 5b shows that, using a combination of hydrophobin, the lipase TfuLip2 and the detergent ARIEL® Color Liquid, by increasing the concentration of detergent and the concentration of hydrophobin, an improved washing effect can be achieved (in particular with 0.4 g/L detergent and 0.4% hydrophobin).

In addition, Figure 2d illustrates that, when a combination of hydrophobin, the lipase LIPEX® and the detergent ARIEL® Color Powder is used, the performance pattern is not affected by lower levels of detergent (the system reaches plateau at 0.05% hydrophobin). However, at higher concentrations of the detergent, the higher SRI value can be reached (30% at 0.4 g/L detergent). Furthermore, Figure 5d illustrates that, when a combination of hydrophobin, the lipase TfuLip2 and the detergent ARIEL® Color Powder is used, the overall performance of the system improves with increase of the concentration of detergent in the system.

Finally, Figure 1b shows that, when a combination of hydrophobin and the detergent ARIEL® Color Liquid is used in the absence of lipases, there is a small synergistic

effect at low concentrations of hydrophobin (0.01-0.1%) and detergent (below 0.25 g/L).

EXAMPLE 2 - Cloning and expression of *Streptomyces pristinaespiralis* ATCC 2548
5 lipase (SprUp2)

The SprLip2 gene was synthesized by GeneRay (Shanghai, China). The SprLlp2 synthetic gene was cloned into expression plasmid pKB128 by Nhe!/BamHi double digestion and ligation. Plasmid pKB128 is a derivative of plasmid pKB105 (described
10 in U.S. Patent Application Publication No. 2006/0154843) and is the source of the A4 promoter-CelA signal sequence. Plasmid pKB128 contains the Nsil-Mlul-Hpal restriction sites (atgcataegcgtgttaac; SEQ ID No 30) before the BamHI site. The *A. niger* A4 promoter and the CelA truncated signal sequences were at the 5' end of the SprLip2 gene sequence (corresponding to the predicted mature protein), and the
15 11AGS terminator sequence was fused to the 3' end of the SprLip2 gene sequence. The pZQ205 expression vector (Figure 30) was constructed by ligation of pKB128 after digestion with the restriction enzymes Nhel and BamHl, to a similarly digested Sprl_ip2 synthetic gene, followed by transformation of *E. coli* cells. The correct sequence of SprLip2 gene was confirmed by DNA sequencing.

20

Plasmid DNA of pZQ205 was transformed into host *Streptomyes lividans* TK23 protoplast cells (described in U.S. Patent Application Publication No. 2006/0154843). Three transformants were picked and transferred into a seed shake flask (15 ml of TSG medium containing 50 ug/ml of thiostrepton in dimethyl sulfoxide), grown for 2
25 days at 30°C with shaking at 200 rpm. 3 ml of the two-day culture from seed shake flask were transferred to 30 ml of *Streptomyces* modified production medium II for protein production. The production cultures were grown for 2 days at 30°C with shaking at 200 rpm. The protein was secreted into the extracellular medium and filtered culture medium was used to perform the cleaning assay and for biochemical
30 characterization experiments. The dosing was based on total protein determined by a Bradford type assay using the Biorad protein assay (500-0006EDU) and corrected for purity determined by SDS-PAGE using a Criterion stain free system from Bio-Rad.

EXAMPLE 3 - Biochemical characterization of SprLip2

35

The lipase/esterase activity of SprLip2 was tested using para-nitrophenyl butyrate ester (pNB) and para-nitrophenyl palmitate (pNPP) as substrates. A 20mM stock

solution of each substrate (p-nitrophenyl butyrate, pNB, Sigma, CAS 2635-84-9, catalog number N9876) dissolved in dimethyl sulfoxide (Pierce, 20688, Water content <0.2%) and p-nitrophenyl palmitate, pNPP; Sigma, CAS 1492-30-4, catalog number N2752 dissolved in dimethyl sulfoxide) was prepared and stored at -80°C for long term storage. Filtered culture supernatant from SprLip2 expressing cells was serially diluted in assay buffer [50mM HEPES pH 8.2, containing 0.75 mM $CaCl_2$ and 0.25mM $MgCl_2$) containing 2% Polyvinyl Alcohol (PVA) (Sigma)] in 96-well microtiter plates and equilibrated at 25°C. 100 µl of 1:20 diluted substrate (in assay buffer) was added to another microtiter plate. The plate was equilibrated to 25°C for 10 minutes with shaking at SOOrpm. 10 µl of enzyme solution from dilution plate was added to the substrate containing plate to initiate reaction. The plate was immediately transferred to a spectrophotometer capable of kinetic measurements equilibrated at 25°C. The absorbance change in kinetic mode was read for 5 minutes at 410nm. The background rate (with no enzyme) was subtracted from the rate of the test samples. Sample concentration was determined as:

Sample concentration = (unknown Rate x standard concentration) / standard rate

Results are shown in Figures 32 (pNB hydrolysis) and 33 (pNPP hydrolysis). (relative rates of hydrolysis.).]

EXAMPLE 4 - Triglyceride hydrolysis by SprLip2

This assay was designed to measure release of fatty acids from triglyceride substrate by lipases. The assay consists of a hydrolysis reaction where incubation of lipase with a triglyceride emulsion results in liberation of fatty acids and thus a reduction in the turbidity of the emulsified substrate. The triglyceride substrate used for the assay was glyceryl trioctanoate (Sigma, CAS 538-23-8, catalog number T9126-100ML). Emulsified trioctanoate (0.75% (v/v or w/v)) was prepared by mixing 50 ml of the gum arabic (Sigma, CAS 9000-01-5, catalog number G9752; 10 mg/ml gum arabic solution made in 50 mM HEPES pH8.2) or detergent solution (0.1% heat inactivated Tide® Cold Water detergent, Procter & Gamble, Cincinnati, OH, USA, (containing 0.75 mM $CaCl_2$ and 0.25mM $MgCl_2$) in 50 mM HEPES pH8.2) with 375 µl of triglyceride. The solutions were mixed and sonicated for at least 2 minutes to prepare a stable emulsion. 200 µl of emulsified substrate was added to a 96-well microtiter plate. 20 µl of serially diluted enzyme sample (filtered culture supernatant from cells expressing SprLip2) were added to the substrate containing plate. The plate was

covered with a plate sealer and incubated at 20°C for 20 minutes. After incubation, the presence of fatty acids in solution was detected as increase in absorbance at 550nm using the HR Series NEFA-HR (2) NEF.A kit (Wako Chemicals GmbH, Germany) as indicated by the manufacturer. Results are shown in Figures 34 (no
5 detergent) and 35 (with detergent).

EXAMPLE 5 - Cleaning performance of SprLip2

The cleaning performance of SprUp2 was tested in the presence and absence of
10 commercially available heat inactivated detergents. Stock solution of lipase was prepared by diluting 258 µl of the enzyme into 1 ml by distilled water. The detergents used were heat inactivated liquid detergent (ARIEL™ color liquid) and heat inactivated powder detergent (ARIEL™ color powder) from Procter & Gamble, Cincinnati, OH, USA.
15

Stain removal experiments were carried out using a lipid-containing technical stain (CS-61 swatches: cotton, beef fat with colorant, purchased from Center for Testmateriais, Netherlands) in a 24-well plate format (Nunc, Denmark). Each assay well was set to contain a pre-cut 13 mm piece of CS-61 swatch. Swatches were pre-
20 read using a scanner (Microtek Scan Maker 900) and placed in the 24-well plate. The buffers used were 20 mM HEPES pH 8.2 for liquid detergent and 20mM CAPS pH 10.0 for powder detergent. Water hardness was adjusted to 24 degrees French using 15000 ppm 2/1 Ca^{2+}/Mg^{2+} diluted to 2400 ppm for both buffers. The detergents were tested at a concentration of zero: 0.1 g/L; 0.25 g/L; and 0.4 g/L. 1 ml of the
25 appropriate buffer described above was added to each swatch-containing well of the 24-well plate. To initiate the reaction, enzyme samples were added at a volume of 100 µL into each well. The plates were shaken for 30 minutes at 200 rpm at 37°C. After incubation, the reaction buffer was removed and the fabric in each well was rinsed three times with 1 mL distilled water. The rinsed swatches were dried at 50°C
30 for 4 hours and their reflectance was measured. Cleaning performance was quantified after a single wash cycle. Stain removal was calculated as the difference of the post- and pre-cleaning RGB measurements for each swatch. RGB measurements were taken with a scanner (Microtek Scan Maker 900). Stain Removal Index values (SRI) of the washed fabric were calculated in relation to the
35 unwashed fabrics using the formula:

% Soil Removal(RGB) = (Soil removal $\Delta E_{(RGB)}$/ Initial soil $\Delta E_{(RGB)}$) X 100%

Where:

Soil removal $\Delta E_{(RGB)} = \sqrt{((R_{after} - R_{before})^2 + (G_{after} - G_{before})^2 + (B_{after} - B_{before})^2)}$

And:

Initial soil $\Delta E_{(RGB)} = \sqrt{((R_{ref} - R_{before})^2 + (G_{ref} - G_{before})^2 + (B_{ref} - B_{before})^2)}$

5 RGB_{ref} values are the values of the unsoiled cotton (white).

Results are shown in Figure 36.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and 10 system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes 15 for carrying out the invention which are obvious to those skilled in chemistry, biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

CLAIMS

1. A composition comprising:
   (a) a lipolytic enzyme; and
   (fa) a hydrophobin having the genera! formula (I):



$$(Y_1)_n\text{-}B_1\text{-}(X_1)_a\text{-}B_2\text{-}(X_2)_b\text{-}B_3\text{-}(X_3)_c\text{-}B_4\text{-}(X_4)_d\text{-}B_5\text{-}(X_5)_e\text{-}B_6\text{-}(X_6)_f\text{-}B_7\text{-}(X_7)_g\text{-}B_8\text{-}(Y_2)_m \quad (I)$$

   wherein:
   m and n are independently 0 to 2000;
   B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu, Ala, Pro, Ser, Thr, Met or Gly, at least 6 of the residues B_1 through B_8 being Cys;
   X_1, X_2, X_3, X_4, X_5, X_6, X_7, Y_1 and Y_2 independently represent any amino acid;
   a is 1 to 50;
   b is 0 to 5;
   c is 1 to 100;
   d is 1 to 100;
   e is 1 to 50;
   f is 0 to 5; and
   g is 1 b 100.

2. A composition according to claim 1, wherein the lipolytic enzyme has triacylglycerol hydrolysing activity (E.G. 3.1.1.3).

3. A composition according to claim 1 or claim 2, wherein the lipolytic enzyme is a GX lipolytic enzyme, wherein G is glycine and X is an oxyanion hole-forming amino acid residue, wherein the GX lipolytic enzyme belongs to an alpha/beta hydrolase superfamily selected from the group consisting of abH23, abH25, and abH1 5.

4. A composition according to any one of claims 1 to 3, additionally comprising:
   (c) a detergent.

5. A composition comprising:
   (a) a GX lipolytic enzyme, wherein G is glycine and X is an oxyanion hole-forming amino acid residue;

(b) a hydrophobin having the general formula (I):



$$(Y_1)_n\text{-}B_1\text{-}(X_1)_a\text{-}B_2\text{-}(X_2)_b\text{-}B_3\text{-}(X_3)_c\text{-}B_4\text{-}(X_4)_d\text{-}B_5\text{-}(X_5)_e\text{-}B_6\text{-}(X_6)_f\text{-}B_7\text{-}(X_7)_g\text{-}B_8\text{-}(Y_2)_m \quad \textbf{(I)}$$

wherein:

m and n are independently 0 to 2000;

B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu, Ala, Pro, Ser, Thr, Met or Gly, at least 6 of the residues B_1 through B_8 being Cys;

X_1, X_2, X_3, X_4, X_5, X_6, X_7, Y_1 and Y_2 independently represent any amino acid;

a is 1 to 50;

b is 0 to 5;

c is 1 to 100;

d is 1 to 100;

e is 1 to 50;

f is 0 to 5; and

g is 1 to 100; and

(c) a detergent.

6. A composition according to claim 5, wherein the GX lipolytic enzyme belongs to an alpha/beta hydrolase superfamily selected from the group consisting of abH23, abH25, abH16 and abH15.

7. **A** composition according to claim 6, wherein the **GX** lipolytic enzyme belongs to an alpha/beta hydrolase superfamily selected from the group consisting of abH23.01 , abH 25.01, abH16.01 and abH15.02.

8. **A** composition according to any one of claims 3 to 7, wherein the oxyanion hole forming residue **X** is selected from the group consisting of **M, Q, F, S, T, A,** L and I.

9. **A** composition according to claim 3 or claim 4, wherein the **GX** lipolytic enzyme belongs to an alpha/beta hydrolase superfamily selected from the group consisting of abH23.01, abH 25.01 and abH15.02.

10. A composition according to any one of claims 3 to 9, wherein the GX iipolytic enzyme is obtained or obtainable from a filamentous fungus.

11. A composition according to any one of claims 3 to 10, wherein the GX lipolytic enzyme belongs to the *Rhizopus meihei* like homologous family abH23.01 .

12. A composition according to any one of claims 3 b 11, wherein the GX iipolytic enzyme is classified in homologous family abH23.01 and is obtained or obtainable from a fungus of a genus selected from the group consisting of *Thermomyces, Fusarium, Aspergillus* and *Rhizopus.*

13. A composition according to claim 12, wherein the GX lipolytic enzyme is classified in homologous family abH23.01 and is obtained or obtainable from a fungal species selected from the group consisting of *Thermomyces lanuginosus, Fusarium hetereosporum, Aspergillus tubiengisis, Aspergillus fumigatus* and *Rhizopus arrihzus.*

14. A composition according to any preceding claim, wherein the iipolytic enzyme is present in a concentration of 0.001 to 20 ppm by weight of the total weight of the composition.

15. A composition according to any preceding claim, wherein the lipolytic enzyme is present in a concentration of 0.01 to 2 ppm by weight of the total weight of the composition.

16. A composition according to any preceding claim, wherein the hydrophobin has a sequence of between 40 and 120 amino acids in the hydrophobin core.

17. A composition according to any preceding claim, wherein the hydrophobin has the general formula (II):

$$(Y_1)_n\text{-}B_1\text{-}(X_1)_a\text{-}B_2\text{-}(X_2)_b\text{-}B_3\text{-}(X_3)_c\text{-}B_4\text{-}(X_4)_d\text{-}B_5\text{-}(X_5)_e\text{-}B_6\text{-}(X_6)_f\text{-}B_7\text{-}(X_7)_g\text{-}B_8\text{-}(Y_2)_m \quad \text{(II)}$$

wherein:

m and n are independently 0 to 20;

B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu, Ala, Pro, Ser, Thr, Met or Gly, at least 7 of the residues B_1 through B_8 being Cys;

a is 3 to 25;

b is 0 to 2;

c is 5 to 50;

d is 2 to 35;

e is 2 to 15;

f is 0 to 2; and

g is 3 to 35.

18. A composition according to any preceding claim, wherein the hydrophobin has the general formula (III):



$$(Y_1)_n-B_1-(X_1)_a-B_2-B_3-(X_3)_c-B_4-(X_4)_d-B_5-(X_5)_e-B_6-B_7-(X_7)_g-B_8-(Y_2)_m \quad (III)$$

wherein:

m and n are independently 0 to 20;

B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu, Ala, Pro, Ser, Thr, Met or Gly, at least 7 of the residues B_1 through B_8 being Cys;

a is 5 to 15;

c is 5 to 40;

d is 4 to 23;

e is 5 to 12; and

g is 6 to 21.

19. A composition according to any preceding claim, wherein all 8 of the residues B_1 through B_8 are Cys.

20. A composition according to any preceding claim, wherein the hydrophobin is a hydrophobin fusion protein.

21. A composition according to any preceding claim, wherein the hydrophobin is obtained or obtainable from a filamentous fungus.

22. A composition according to claim 21, wherein the hydrophobin is obtained or obtainable from a fungus of genus selected from the group consisting of *Cladosporium, Ophistoma, Cryphonectria, Trichoderma, Gibberella, Neurospora, Maganaporthe, Hypocrea, Xanihoria, Emericella, Aspergillus, Paracoccioides, Metarhizium, Pleurotus, Coprinus, Dicotyonema, Flammuiina, Schizophyl!um, Agaricus, Pisolithus, Tricholoma, Pholioka, Talaromyces* and *Agrocybe.*

23. A composition according to any preceding ciairn, wherein the hydrophobin is generated *in situ* in the composition.

24. A composition according to any preceding claim, wherein, in use, the hydrophobin causes the equilibrium surface tension at a water/air interface to reduce to below 45 mN/m.

25. A composition according to any preceding claim, wherein, in use, the hydrophobin causes the surface shear elasticity at a water/air interface to increase to 300-700 mN/m.

26. A composition according to any preceding claim, wherein the hydrophobin is a Class II hydrophobin.

27. A composition according to claim 26, wherein the hydrophobin is a Class II hydrophobin having the generai formula (IV):



$$(Y_1)_n\text{-}B_1\text{-}(X_1)_a\text{-}B_2\text{-}B_3\text{-}(X_3)_c\text{-}B_4\text{-}(X_4)_d\text{-}B_5\text{-}(X_5)_e\text{-}B_6\text{-}B_7\text{-}(X_7)_g\text{-}B_8\text{-}(Y_2)_m \quad \text{(iv)}$$

wherein:

m and n are independently 0 to 200;

B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu, Ala, Ser, Thr, Met or Gly, at least 6 of the residues B_1 through B_8 being Cys;

a is 6 to 12;

c is 8 to 16;

d is 2 to 20;

e is 4 to 12; and

g is 5 to 15.

28. A composition according to claim 26 or claim 27, wherein the hydrophobin is a Class II hydrophobin having the general formula (V):



$$(Y_1)_n\text{-}B_1\text{-}(X_1)_a\text{-}B_2\text{-}B_3\text{-}(X_3)_c\text{-}B_4\text{-}(X_4)_d\text{-}B_5\text{-}(X_5)_e\text{-}B_6\text{-}B_7\text{-}(X_7)_g\text{-}B_8\text{-}(Y_2)_m \quad (V)$$

wherein:

m and n are independently 0 to 10;

B_1, B_2, B_3, B_4, B_5, B_6, B_7 and B_8 are each independently amino acids selected from Cys, Leu or Ser, at least 7 of the residues B_1 through B_8 being Cys;

a is 7 to 11;

c is 11;

d is 4 to 18;

e is 6 to 10; and

g is 7 to 10.

29. A composition according to any one of claims 26 to 28, wherein all 8 of the residues B_1 through B_8 are Cys.

30. A composition according to any one of claims 26 to 29, wherein the group $(X_3)_c$ comprises the sequence motif ZZXZ, wherein Z is an aliphatic amino acid; and X is any amino acid.

31. A composition according to any preceding claim, wherein the hydrophobin is present in a concentration of 0.001% to 5% by weight of the total weight of the composition.

32. A composition according to claim 31, wherein the hydrophobin is present in a concentration of 0.01 % to 0.5% by weight of the total weight of the composition.

33. A composition according to any one of claims 4 to 32, wherein the detergent is present in a concentration of between 0.001 and 5 g/L.

34. A composition according to claim 33, wherein the detergent is present in a concentration of between 0.01 to 0.5 g/L.

35. A composition according to any preceding claim, additionally containing one or more enzymes selected from the group consisting of a protease, an amylase, a

glucoamyiase, a maitogenic amylase, a non-maitogenic amylase, a lipase, a cuiinase, a carbohydrase, a ce'iuiase, a pectinase, a mannanase, an arabinase, a galactanase, a xy!anase, an oxidase, a laccase, and a peroxidase.

36. A composition according to any one of claims 4 to 35, wherein the detergent comprises one or more surfactants.

37. A composition according to claim 36, wherein the surfactants are selected from the group consisting of non-ionic (including semi-polar), anionic, cationic and zwitterionic.

38. A composition according to any one of ciaims 1 to 37, in powder form.

39. A composition according to any one of claims 1 to 37, in liquid form.

40. A method of removing a lipid-based stain from a surface by contacting the surface with a composition according to any one of claims 1 to 39.

41. The use of composition according to any one of claims 1 to 39 to reduce or remove lipid stains from a surface.

42. A method of cleaning a surface, comprising contacting the surface with a composition according to any one of claims 1 to 39.

43. A method of cleaning an item, comprising contacting the item with a composition according to any one of claims 1 to 39.

44. A method according to claim 43, wherein the item is a clothing item.

45. A method according to claim 43, wherein the item is a tableware item.



Fig. 1a



Fig. 1b



Fig. 1c



Fig. 2a



Fig. 2b



Fig. 2c



Fig. 2d



Fig. 2e



Fig. 3a



Fig. 3b



Fig. 3c



Fig. 3d



Fig. 3e



Fig. 4a



Fig. 4b



Fig. 4c



Fig. 4d



Fig. 4e



Fig. 5a



Fig. 5b



Fig. 5c



Fig. 5d



Fig. 5e

Fig. 6

SEQ ID NO: 1

Trichoderma reesei HFBII (Y11894.1)

```
  1 cacattcact caactcctct ttctcaactc tccaaacaca aacattcttt gttgaatacc
 61 aaccatcacc acctttcaag atgcagttct tcgccgtcgc cctcttcgcc accagcgccc
121 tggctgctgt ctgccctacc ggcctcttct ccaaccctct gtgctgtgcc accaacgtcc
181 tcgacctcat tggcgttgac tgcaagaccc gtatgttgaa ttccaatctc tgggcatcct
241 gacattggac gatacagttg acttacacga tgctttacag ctaccatcgc cgtcgacact
301 ggcgccatct tccaggctca ctgtgccagc aagggctcca agcctctttg ctgcgttgct
361 cccgtggtaa gtagtgctcg caatggcaaa gaagtaaaaa gacatttggg cctgggatcg
421 ctaactcttg atatcaaggc cgaccaggct ctcctgtgcc agaaggccat cggcaccttc
481 taaagcaatg gcttgcttta ctgccggcag tctttgagaa ctctgggctc acaaaagacg
541 acttgcatgt atcatggggg ctcgcaaatg ggaggatttg gaggggattg aggctgggtt
601 tggcctatta gaggattgca taatggaaga tttgcgagca ggacatagac gtatctagag
661 ttctagt
```

Fig. 7

SEQ ID NO: 2

Trichoderma reesei HFBII (P79073.1)

```
 1 MQFFAVALFA TSALAAVCPT GLFSNPLCCA TNVLDLIGVD CKTPTIAVDT GAIFQAHCAS
61 KGSKPLCCVA PVADQALLCQ KAIGTF
```

Fig. 8

SEQ ID NO: 3

Trichoderma reesei HFBI (Z68124.1)

```
   1 tttgtatggc tggatctcga aaggcccttg tcatcgccaa gcgtggctaa tatcgaatga
  61 gggacaccga gttgcatatc tcctgatcat tcaaacgaca agtgtgaggt aggcaatcct
 121 cgtatcccat tgctgggctg aaagcttcac acgtatcgca taagcgtctc caaccagtgc
 181 ttaggtgacc cttaaggata cttacagtaa gactgtatta agtcagtcac tctttcactc
 241 gggctttgaa tacgatcctc aatactcccg ataacagtaa gaggatgata cagcctgcag
 301 ttggcaaatg taagcgtaat taaactcagc tgaacggccc ttgttgaaag tctctctcga
 361 tcaaagcaaa gctatccaca gacaagggtt aagcaggctc actcttccta cgccttggat
 421 atgcagcttg gccagcatcg cgcatggcca atgatgcacc cttcacggcc caacggatct
 481 cccgttaaac tcccctgtaa cttggcatca ctcatctgtg atcccaacag actgagttgg
 541 gggctgcggc tggcggatgt cggagcaaag gatcacttca agagcccaga tccggttggt
 601 ccattgccaa tggatctaga ttcggcacct tgatctcgat cactgagaca tggtgagttg
 661 cccggacgca ccacaactcc ccctgtgtca ttgagtcccc atatgcgtct tctcagcgtg
 721 caactctgag acggattagt cctcacgatg aaattaactt ccagcttaag ttcgtagcct
 781 tgaatgagtg aagaaatttc aaaaacaaac tgagtagagg tcttgagcag ctggggtggt
 841 acgcccctcc tcgactcttg ggacatcgta cggcagagaa tcaacggatt cacacctttg
 901 ggtcgagatg agctgatctc gacagatacg tgcttcacca cagctgcagc tacctttgcc
 961 caaccattgc gttccaggat cttgatctac atcaccgcag cacccgagcc aggacggaga
1021 gaacaatccg gccacagagc agcaccgcct tccaactctg ctcctggcaa cgtcacacaa
1081 cctgatatta gatatccacc tgggtgattg ccattgcaga gaggtggcag ttggtgatac
1141 cgactggcca tgcaagacgc ggccgggcta gctgaaatgt ccccgagagg acaattggga
1201 gcgtctatga cggcgtggag acgacgggaa aggactcagc cgtcatgttg tgttgccaat
1261 ttgagattgt tgaccgggaa agggggacg aagaggatgg ctgggtgagg tggtattggg
1321 aggatgcatc attcgactca gtgagcgatg tagagctcca agaatataaa tatcccttct
1381 ctgtcttctc aaaatctcct tccatcttgt ccttcatcag caccagagcc agcctgaaca
1441 cctccagtca acttccctta ccagtacatc tgaatcaaca tccattcttt gaaatctcac
1501 cacaaccacc atcttcttca aaatgaagtt cttcgccatc gccgctctct ttgccgccgc
1561 tgccgttgcc cagcctctcg aggaccgcag caacggcaac ggcaatgttt gccctcccgg
1621 cctcttcagc aacccccagt gctgtgccac ccaagtcctt ggcctcatcg gccttgactg
1681 caaagtccgt aagttgagcc ataacataag aatcctcttg acggaaatat gccttctcac
1741 tcctttaccc ctgaacagcc tcccagaacg tttacgacgg caccgacttc cgcaacgtct
1801 gcgccaaaac cggcgcccag cctctctgct gcgtggcccc cgttgtaagt tgatgcccca
1861 gctcaagctc cagtctttgg caaacccatt ctgacaccca gactgcaggc cggccaggct
1921 cttctgtgcc agaccgccgt cggtgcttga gatgcccgcc cggggtcaag gtgtgcccgt
1981 gagaaagccc acaaagtgtt gatgaggacc atttccggta ctgggaaagt tggctccacg
2041 tgtttgggca ggtttgggca agttgtgtag atattccatt cgtacgccat tcttattctc
2101 caatatttca gtacactttt cttcataaat caaaaagact gctattctct ttgtgacatg
2161 ccggaaggga acaattgctc ttggtctctg ttatttgcaa gtaggagtgg gagattcgcc
2221 ttagagaaag tagagaagct gtgcttgacc gtggtgtgac tcgacgagga tggactgaga
2281 gtgttaggat taggtcgaac gttgaagtgt atacaggatc gtctggcaac ccacggatcc
2341 tatgacttga tgcaatggtg aagatgaatg acagtgtaag aggaaaagga aatgtccgcc
2401 ttcagctgat atccacgcca atgatacagc gatatacctc caatatctgt gggaacgaga
2461 catgacatat ttgtgggaac aacttcaaac agcgagccaa gacctcaata tgcacatcca
2521 aagccaaaca ttggcaagac gagagacagt cacattgtcg tcgaaagatg gcatcgtacc
2581 caaatcatca gctctcatta tcgcctaaac cacagattgt ttgccgtccc ccaactccaa
2641 aacgttacta caaaagacat gggcgaatgc aaagacctga aagcaaaccc tttttgcgac
2701 tcaattccct cctttgtcct cggaatgatg atccttcacc aagtaaaaga aaaagaagat
2761 tgagataata catgaaaagc acaacggaaa cgaaagaacc aggaaaagaa taaatctatc
2821 acgcaccttg tccccacact aaaagcaaca gggggggtaa aatgaaat
```

Fig. 9

SEQ ID NO: 4

Trichoderma reesei HFBI (P52754.1)

```
 1 MKFFAIAALF AAAAVAQPLE DRSNGNGNVC PPGLFSNPQC CATQVLGLIG LDCKVPSQNV
61 YDGTDFRNVC AKTGAQPLCC VAPVAGQALL CQTAVGA
```

Fig. 10

SEQ ID NO: 5

Schizophyllum commune SC3 (M32329.1)

```
  1 agtcgaacac cccagttcaa ctaccccagc ccttccttcc ttcgctatcc ttccttacaa
 61 cctgctcgcc atgttcgccc gtctccccgt cgtgttcctc tacgccttcg tcgcgttcgg
121 cgccctcgtc gctgccctcc caggtggcca cccgggcacg acgtacgtcg acctctcacc
181 gtcctctaat gtcttgctga tgaagccccg tatagcacgc cgccggttac gacgacggtg
241 acggtgacca cggtgagtag ctttctcgcc gtcgacgact cgaacgcatt ggctaatttt
301 tgctcatagc cgccctcgac gacgaccatc gccgccggtg gcacgtgtac tacggggtcg
361 ctctcttgct gcaaccaggt tcaatcggta cgtacatcaa agcggcacga ccaggcatct
421 cagctgacgg ccacatcgta caggcgagca gcagccctgt taccgccctc ctcggcctgc
481 tcggcattgt cctcagcgac ctcaacgttc tcgttggcat cagctgctct cccctcactg
541 tgagatcttt ttgttcactg tcccaattac tgcgcactga cagactttgc caggtcatcg
601 gtgtcggagg cagcggctgt tcggcgcaga ccgtctgctg cgaaaacacc caattcgtat
661 gtatactttc catgcgtgtc cctttctccg ctaatcatct gtagaacggg ctgatcaaca
721 tcggttgcac ccccatcaac atcctctgag caggtgaacg cgcctgtcgg tgggatattc
781 gggcgacggg agcctcgggc aatctgagcc tcgttactgc ctagcaaatt cggaatccct
841 tcgatgtcat agggtcgcgg acaagtgatc gtcttgctac atactccaag gtgttgactc
901 attccctcag ataatgaaca ttgttgttgt tgttgtttgt tctct
```

Fig. 11

SEQ ID NO: 6

Schizophyllum commune SC3 (AAA96324.1)

```
  1 MFARLPVVFL YAFVAFGALV AALPGGHPGT TTPPVTTTVT VTTPPSTTTI AAGGTCTTGS
 61 LSCCNQVQSA SSSPVTALLG LLGIVLSDLN VLVGISCSPL TVIGVGGSGC SAQTVCCENT
121 QFNGLINIGC TPINIL
```

Fig. 12

SEQ ID NO: 7

Neurospora crassa EAS (X67339.1)

```
  1 atcatcagca tcaacatctt cacttcacaa catcttctca accttccaac tcaccttcca
 61 aaccaccttc aaaaccaact cccagcttct ttcagcaaac ccccaaccgc caaaatgcag
121 ttcaccagcg tcttcaccat cctcgccatt gccatgaccg ccgctgcggc cccggctgag
181 gttgttcccc gcgccaccac catcggcccc aacacctgct ccatcgacga ctacaagcct
241 tactgctgcc agtctatgtc cggccccgcc ggctcccctg gtctcctcaa cctcatcccc
301 gtcgacctca gcgcctcgct cggctgcgtt gtcggtgtca tcggctccca atgtggtgcc
361 agcgtcaagt gctgcaagga cgatgttacc aacaccggca actccttcct catcatcaac
421 gctgccaact gcgttgccta agtgtttacg cggcaacagc gcaaagtcta ggcaatgcct
481 tgttctcaac gctgctgcca gtccagcacc cccttctgc agcaaggagc ccccttctgc
541 tggactggca gcacaacgag ctgctactac aacacaagca tcatgcctgg acgcaacaga
601 agccgataat cttgggtttt ggttttgggg gatgaaggtg atgagttgat ggattggatc
661 gatatcttac aatgcgtgtc tcttcctgtt aagatctgct ttactatttt cctattttct
721 tttacacata gctatgtatc actaaggcct ggtgattaat acactctctt aaccct
```

Fig. 13

SEQ ID NO: 8

Neurospora crassa EAS (AAB24462.1)

```
 1 MQFTSVFTIL AIAMTAAAAP AEVVPRATTI GPNTCSIDDY KPYCCQSMSG PAGSPGLLNL
61 IPVDLSASLG CVVGVIGSQC GASVKCCKDD VTNTGNSFLI INAANCVA
```

Fig. 14

SEQ ID NO: 9

Talaromyces thermophilus TT1

(DNA sequence encoding the precursor TT1 hydrophobin, SEQ ID NO:4 of US 7241734)

```
  1 atgaagttcg ccggtgtctt gcttgctgtc gccgctgcgg cgactgccct gccaaacgtc
 61 ggtcccagtg ggaagacggc tcacaagccg caccaggagc ctttctggcc tgtgcagcag
121 gacgtgaccg tggaacaggc caaggctatc tgtggtgaag gcaaccaggt cgcttgctgc
181 aacgaggtca gctacgcggg cgacaccacc gaaatcgcga ccggcccct ggctggcacc
241 ctcaaggacc tgctcggcgg caagaacggc gccaagggcc tgggtctctt cgacaagtgc
301 tcgcgtctca atgtcgatct cctgcttggc ctgtcgagcc tcatcaacca agaatgcaag
361 cagcacattg cctgctgcca gggcaacgag gccgattcct ccaacgacct catcggtctc
421 aacattcctt gcattgccct tggctcgctg ctg
```

Fig. 15

SEQ ID NO: 10

Talaromyces thermophilus TT1
(amino acid sequence of the precursor TT1 hydrophobin, SEQ ID NO:3 US 7241734)

```
  1 MKFAGVLLAV AAAATALPNV GPSGKTAHKP HQEPFWPVQQ DVTVEQAKAI CGEGNQVACC
 61 NEVSYAGDTT EIATGPLAGT LKDLLGGKNG AKGLGLFDKC SRLNVDLLLG LSSLINQECK
121 QHIACCQGNE ADSSNDLIGL NIPCIALGSL L
```

Fig. 16

SEQ ID NO: 11

EVSQDLFNQFNLFAQYSAAAYCGKNNDAPAGTNITCTGNACPEVEKADATFLYSFEDSGVGD
VTGFLALDNTNKLIVLSFRGSRSIENWIGNLNFDLKEINDICSGCRGHDGFTSSWRSVADTLRQ
KVEDAVREHPDYRVVFTGHSLGGALATVAGADLRGNGYDIDVFSYGAPRVGNRAFAEFLTV
QTGGTLYRITHTNDIVPRLPPREFGYSHSSPEYWIKSGTLVPVRRRDIVKIEGIDATGGNNQPNIP
DIPAHLWYFGLIGTCL

Fig. 17

SEQ ID NO: 12

MLPWKRALRPLSALMLAVAVALTPAATATADTTTAAPSSGWNDYDCKPSAAHPRPVVLV
HGTLGNSVDNWLVLAPYLVKRGYCVFSLDYGQLPGVPFFHGLGPVDKSAEQLDAYVDKVLA
ATGAPEADIVGHSQGGMMPRYYLKFLGGAAKVNALVGIAPSNHGTDLNGFTALLPYFPGAAD
LLGRHTPALADQVTGSAFLTRLNADGDTVAGVRYTVIATRYDEVVTPWRSQYLSGPNVRNVL
LQDLCPLDLSEHVAIGVFDLIAYHEVANALDPAHATPTTCASVFG

Fig. 18

SEQ ID NO: 13

Ala Val Gly Val Thr Ser Thr Asp Phe Thr Asn Phe Lys Phe Tyr Ile Gln His Gly Ala Ala Ala Tyr
Cys Asn Ser Gly Thr Ala Ala Gly Ala Lys Ile Thr Cys Ser Asn Asn Gly Cys Pro Thr Ile Glu Ser
Asn Gly Val Thr Val Val Ala Ser Phe Thr Gly Ser Lys Thr Gly Ile Gly Gly Tyr Val Ser Thr Asp
Ser Ser Arg Lys Glu Ile Val Val Ala Ile Arg Gly Ser Ser Asn Ile Arg Asn Trp Leu Thr Asn Leu
Asp Phe Asp Gln Ser Asp Cys Ser Leu Val Ser Gly Cys Gly Val His Ser Gly Phe Gln Asn Ala
Trp Ala Glu Ile Ser Ala Gln Ala Ser Ala Ala Val Ala Lys Ala Arg Lys Ala Asn Pro Ser Phe Lys
Val Val Ala Thr Gly His Ser Leu Gly Gly Ala Val Ala Thr Leu Ser Ala Ala Asn Leu Arg Ala Ala
Gly Thr Pro Val Asp Ile Tyr Thr Tyr Gly Ala Pro Arg Val Gly Asn Ala Ala Leu Ser Ala Phe Ile
Ser Asn Gln Ala Gly Gly Glu Phe Arg Val Thr His Asp Lys Asp Pro Val Pro Arg Leu Pro Pro
Leu Ile Phe Gly Tyr Arg His Thr Thr Pro Glu Tyr Trp Leu Ser Gly Gly Gly Gly Asp Lys Val Asp
Tyr Ala Ile Ser Asp Val Lys Val Cys Glu Gly Ala Ala Asn Leu Met Cys Asn Gly Gly Thr Leu
Gly Leu Asp Ile Asp Ala His Leu His Tyr Phe Gln Ala Thr Asp Ala Cys Asn Ala Gly Gly Phe Ser
Trp Arg

Fig. 19

Lipase 3 – SEQ ID NO. 29

```
Met Phe Ser Gly Arg Phe Gly Val Leu Leu Thr Ala Leu Ala Ala Leu
-27     -25                 -20                 -15

Gly Ala Ala Ala Pro Ala Pro Leu Ala Val Arg Ser Val Ser Thr Ser
    -10                  -5                   1               5

Thr Leu Asp Glu Leu Gln Leu Phe Ala Gln Trp Ser Ala Ala Ala Tyr
                 10                  15                  20

Cys Ser Asn Asn Ile Asp Ser Lys Asp Ser Asn Leu Thr Cys Thr Ala
             25                  30                  35

Asn Ala Cys Pro Ser Val Glu Glu Ala Ser Thr Thr Met Leu Leu Glu
         40                  45                  50

Phe Asp Leu Thr Asn Asp Phe Gly Gly Thr Ala Gly Phe Leu Ala Ala
     55                  60                  65

Asp Asn Thr Asn Lys Arg Leu Val Val Ala Phe Arg Gly Ser Ser Thr
 70                  75                  80                  85

Ile Glu Asn Trp Ile Ala Asn Leu Asp Phe Ile Leu Glu Asp Asn Asp
                 90                  95                 100

Asp Leu Cys Thr Gly Cys Lys Val His Thr Gly Phe Trp Lys Ala Trp
            105                 110                 115

Glu Ser Ala Ala Asp Glu Leu Thr Ser Lys Ile Lys Ser Ala Met Ser
        120                 125                 130

Thr Tyr Ser Gly Tyr Thr Leu Tyr Phe Thr Gly His Ser Leu Gly Gly
    135                 140                 145

Ala Leu Ala Thr Leu Gly Ala Thr Val Leu Arg Asn Asp Gly Tyr Ser
150                 155                 160                 165

Val Glu Leu Tyr Thr Tyr Gly Cys Pro Arg Ile Gly Asn Tyr Ala Leu
                170                 175                 180

Ala Glu His Ile Thr Ser Gln Gly Ser Gly Ala Asn Phe Arg Val Thr
            185                 190                 195

His Leu Asn Asp Ile Val Pro Arg Val Pro Pro Met Asp Phe Gly Phe
        200                 205                 210

Ser Gln Pro Ser Pro Glu Tyr Trp Ile Thr Ser Gly Asn Gly Ala Ser
    215                 220                 225

Val Thr Ala Ser Asp Ile Glu Val Ile Glu Gly Ile Asn Ser Thr Ala
230                 235                 240                 245

Gly Asn Ala Gly Glu Ala Thr Val Ser Val Val Ala His Leu Trp Tyr
                250                 255                 260

Phe Phe Ala Ile Ser Glu Cys Leu Leu  *
            265                 270
```

Fig. 19a

SEQ ID No: 14

```
Ser Val Ser Thr Ser
  1             5

Thr Leu Asp Glu Leu Gln Leu Phe Ala Gln Trp Ser Ala Ala Ala Tyr
                10                  15                  20

Cys Ser Asn Asn Ile Asp Ser Lys Asp Ser Asn Leu Thr Cys Thr Ala
            25                  30                  35

Asn Ala Cys Pro Ser Val Glu Glu Ala Ser Thr Thr Met Leu Leu Glu
        40                  45                  50

Phe Asp Leu Thr Asn Asp Phe Gly Gly Thr Ala Gly Phe Leu Ala Ala
    55                  60                  65

Asp Asn Thr Asn Lys Arg Leu Val Val Ala Phe Arg Gly Ser Ser Thr
 70                  75                  80                  85

Ile Glu Asn Trp Ile Ala Asn Leu Asp Phe Ile Leu Glu Asp Asn Asp
                90                  95                 100

Asp Leu Cys Thr Gly Cys Lys Val His Thr Gly Phe Trp Lys Ala Trp
            105                 110                 115

Glu Ser Ala Ala Asp Glu Leu Thr Ser Lys Ile Lys Ser Ala Met Ser
        120                 125                 130

Thr Tyr Ser Gly Tyr Thr Leu Tyr Phe Thr Gly His Ser Leu Gly Gly
    135                 140                 145

Ala Leu Ala Thr Leu Gly Ala Thr Val Leu Arg Asn Asp Gly Tyr Ser
150                 155                 160                 165

Val Glu Leu Tyr Thr Tyr Gly Cys Pro Arg Ile Gly Asn Tyr Ala Leu
                170                 175                 180

Ala Glu His Ile Thr Ser Gln Gly Ser Gly Ala Asn Phe Arg Val Thr
            185                 190                 195

His Leu Asn Asp Ile Val Pro Arg Val Pro Pro Met Asp Phe Gly Phe
        200                 205                 210

Ser Gln Pro Ser Pro Glu Tyr Trp Ile Thr Ser Gly Asn Gly Ala Ser
    215                 220                 225

Val Thr Ala Ser Asp Ile Glu Val Ile Glu Gly Ile Asn Ser Thr Ala
230                 235                 240                 245

Gly Asn Ala Gly Glu Ala Thr Val Ser Val Val Ala His Leu Trp Tyr
                250                 255                 260

Phe Phe Ala Ile Ser Glu Cys Leu Leu  *
            265                 270
```

Fig. 20

SEQ ID NO: 15

VYITEVSQLNTSELRGEELLEQVEEIAAISGKGKVNLVGHSHGGPTVRYVAAVRPDLVASVTS
VGAPHKGSDTADFIRQIPPGSAGEAIVAGIVNGLGALINFLSGSSSTSPQNALGALESLNSEGAA
AFNAKYPQGIPTSACGEGAYKVNGVSYYSWSGTSPLTNVLDVSDLLLGASSLTFDEPNDGLVG
RCSSHLGKVIRDDYRMNHLDEVNQTFGLTSLFETDPVTVYRQQANRLKLAGL

Fig. 21

SEQ ID NO: 16

ANPYERGPNPTDALLEASSGPFSVSEENVSRLSASGFGGGTIYYPRENNTYGAVAISPGYTGTE
ASIAWLGERIASHGFVVITIDTITTLDQPDSRAEQLNAALNHMINRASSTVRSRIDSSRLAVMGH
SMGGGGTLRLASQRPDLKAAIPLTPWHLNKNWSSVTVPTLIIGADLDTIAPVATHAKPFYNSLP
SSISKAYLELDGATHFAPNIPNKIIGKYSVAWLKRFVDNDTRYTQFLCPGPRDGLFGEVEEYRS
TCPF

Fig. 22

SEQ ID NO: 17

DTTTAAPSSGWNDYDCKPSAAHPRPVVLVHGTLGNSVDNWLVLAPYLVKRGYCVFSLDYGQ
LPGVPFFHGLGPVDKSAEQLDAYVDKVLAATGAPEADIVGHSQGGMMPRYYLKFLGGAAKV
NALVGIAPSNHGTDLNGFTALLPYFPGAADLLGRHTPALADQVTGSAFLTRLNADGDTVAGV
RYTVIATRYDEVVTPWRSQYLSGPNVRNVLLQDLCPLDLSEHVAIGVFDLIAYHEVANALDPA
HATPTTCASVFG

Fig. 23

SEQ ID NO: 18

MRSSLVLFFVSAWTALASPIRREVSQDLFNQFNLFAQYSAAAYCGKNNDAPAGTNITCTGNAC
PEVEKADATFLYSFEDSGVGDVTGFLALDNTNKLIVLSFRGSRSIENWIGNLNFDLKEINDICSG
CRGHDGFTSSWRSVADTLRQKVEDAVREHPDYRVVFTGHSLGGALATVAGADLRGNGYDID
VFSYGAPRVGNRAFAEFLTVQTGGTLYRITHTNDIVPRLPPREFGYSHSSPEYWIKSGTLVPVR
RRDIVKIEGIDATGGNNQPNIPDIPAHLWYFGLIGTCL

Fig. 24

SEQ ID NO: 19

MNNKKTLLALCIGSSLLLSGPAEAGLFGSTGYTKTKYPIVLTHGLLGFDSILGVDYWYGIPSSL
RSDGASVYITEVSQLNTSELRGEELLEQVEEIAAISGKGKVNLVGHSHGGPTVRYVAAVRPDL
VASVTSVGAPHKGSDTADFIRQIPPGSAGEAIVAGIVNGLGALINFLSGSSSTSPQNALGALESL
NSEGAAAFNAKYPQGIPTSACGEGAYKVNGVSYYSWSGTSPLTNVLDVSDLLLGASSLTFDEP
NDGLVGRCSSHLGKVIRDDYRMNHLDEVNQTFGLTSLFETDPVTVYRQQANRLKLAGL

Fig. 25

SEQ ID No. 20

MAVMTPRRERSSLLSRALQVTAAAATALVTAVSLAAPAHAANPYERGPNPTDALLEASSGPFS
VSEENVSRLSASGFGGGTIYYPRENNTYGAVAISPGYTGTEASIAWLGERIASHGFVVITIDTITT
LDQPDSRAEQLNAALNHMINRASSTVRSRIDSSRLAVMGHSMGGGGTLRLASQRPDLKAAIPL
TPWHLNKNWSSVTVPTLIIGADLDTIAPVATHAKPFYNSLPSSISKAYLELDGATHFAPNIPNKII
GKYSVAWLKRFVDNDTRYTQFLCPGPRDGLFGEVEEYRSTCPF

Fig. 26

SEQ ID No. 21

```
  1   EAEAAVGVTS TDFTNFKFYI QHGAAAYCNS GTAAGAKITC SNNGCPTIES
 51   NGVTVVASFT GSKTGIGGYV STDSSRKEIV VAIRGSSNIR NWLTNLDFDQ
101   SDCSLVSGCG VHSGFQNAWA EISAQASAAV AKARKANPSF KVVATGHSLG
151   GAVATLSAAN LRAAGTPVDI YTYGAPRVGN AALSAFISNQ AGGEFRVTHD
201   KDPVPRLPPL IFGYRHTTPE YWLSGGGGDK VDYAISDVKV CEGAANLMCN
251   GGTLGLDIDA HLHYFQATDA CNAGGFSWR
```

Fig. 27

SEQ ID No. 22

**GACACCACGACCGCGGCACCCTCCTCGGGCTGGAACGACTACGACTGCAAG
CCGTCCGCCGCGCACCCCCGCCCCGTGGTCCTCGTCCACGGCACGCTCGGC
AACAGCGTGGACAACTGGCTGGTCCTGGCCCCGTACCTCGTCAAGCGCGGC
TACTGCGTGTTCTCCCTGGACTACGGCCAGCTGCCGGGCGTGCCCTTCTTCC
ACGGCCTGGGCCCGGTGGACAAGAGCGCCGAGCAGCTGGACGCCTACGTGG
ACAAGGTGCTCGCCGCCACCGGCGCCCCGGAGGCGGACATCGTCGGGCACT
CGCAGGGGGGCATGATGCCCCGGTACTACCTGAAGTTCCTCGGCGGGGCGG
CCAAGGTCAACGCCCTGGTGGGCATCGCCCCCTCGAACCACGGGACGGACC
TCAACGGCTTCACCGCCCTCCTGCCGTACTTCCCGGGCGCCGCCGACCTCCT
CGGCCGGCACACCCCGGCGCTGGCCGACCAGGTCACCGGGAGCGCGTTCCT
GACCCGCCTGAACGCGGACGGCGACACGGTCGCGGGGGTCCGCTACACCGT
CATCGCCACGCGCTACGACGAGGTCGTCACCCCCTGGCGGTCCCAGTACCT
GAGCGGCCCGAACGTCCGGAACGTGCTGCTCCAGGACCTGTGCCCCCTCGA
CTTGAGCGAACACGTGGCCATCGGCGTGTTCGACCTCATCGCATACCACGAG
GTCGCCAACGCCCTGGACCCGGCGCACGCCACCCCCACGACCTGCGCGTCC
GTCTTCGGC**

Fig. 28

SEQ ID No. 23

ATGGGCTTTGGGAGCGCTCCCATCGCGTTGTGTCCGCTTCGCACGAGGAGGAACGCTTTGA
AACGCCTTTTGGCCCTGCTCGCGACCGGCGTGTCGATCGTCGGCCTGACTGCGCTAGCCGG
CCCCCCGGCACAGGCCGACACCACGACCGCGGCACCCTCCTCGGGCTGGAACGACTACGA
CTGCAAGCCGTCCGCCGCGCACCCCCGCCCCGTGGTCCTCGTCCACGGCACGCTCGGCAAC
AGCGTGGACAACTGGCTGGTCCTGGCCCCGTACCTCGTCAAGCGCGGCTACTGCGTGTTCT
CCCTGGACTACGGCCAGCTGCCGGGCGTGCCCTTCTTCCACGGCCTGGGCCCGGTGGACA
AGAGCGCCGAGCAGCTGGACGCCTACGTGGACAAGGTGCTCGCCGCCACCGGCGCCCCGG
AGGCGGACATCGTCGGGCACTCGCAGGGGGGCATGATGCCCCGGTACTACCTGAAGTTCC
TCGGCGGGGCGGCCAAGGTCAACGCCCTGGTGGGCATCGCCCCCTCGAACCACGGGACGG
ACCTCAACGGCTTCACCGCCCTCCTGCCGTACTTCCCGGGCGCCGCCGACCTCCTCGGCCG
GCACACCCCGGCGCTGGCCGACCAGGTCACCGGGAGCGCGTTCCTGACCCGCCTGAACGC
GGACGGCGACACGGTCGCGGGGGTCCGCTACACCGTCATCGCCACGCGCTACGACGAGGT
CGTCACCCCCTGGCGGTCCCAGTACCTGAGCGGCCCGAACGTCCGGAACGTGCTGCTCCA
GGACCTGTGCCCCCTCGACTTGAGCGAACACGTGGCCATCGGCGTGTTCGACCTCATCGCA
TACCACGAGGTCGCCAACGCCCTGGACCCGGCGCACGCCACCCCCACGACCTGCGCGTCC
GTCTTCGGC

Fig. 29

SEQ ID No. 24

MGFGSAPIALCPLRTRRNALKRLLALLATGVSIVGLTALAGPPAQADTTTAAPSSGWNDYDCK
PSAAHPRPVVLVHGTLGNSVDNWLVLAPYLVKRGYCVFSLDYGQLPGVPFFHGLGPVDKSAE
QLDAYVDKVLAATGAPEADIVGHSQGGMMPRYYLKFLGGAAKVNALVGIAPSNHGTDLNGF
TALLPYFPGAADLLGRHTPALADQVTGSAFLTRLNADGDTVAGVRYTVIATRYDEVVTPWRS
QYLSGPNVRNVLLQDLCPLDLSEHVAIGVFDLIAYHEVANALDPAHATPTTCASVFG

Fig. 30



Fig. 31



Fig. 32



Fig. 33



Fig. 34



Fig. 35



Fig. 36

SEQ ID No. 25

MKCCRIMFVLLGLWFVFGLSVPGGRTEAASLRANDAPIVLLHGFTGWGREEMFGFKYWGGVRGDIEQWLN
DNGYRTFTLAVGPLSSNWDRACEAYAQLVGGTVDYGAAHAAKHGHARFGRTYPGLLPELKRGGRIHIIAH
SQGGQTARMLVSLLENGSQEEREYAKAHNVSLSPLFEGGHHFVLSVTTIATPHDGTTLVNMVDFTDRFFD
LQKAVLEAAAVASNVPYTSQVYDFKLDQWGLRRQPGESFDHYFERLKRSPVWTSTDTARYDLSVSGAEKL
NQWVQASPNTYYLSFSTERTYRGALTGNHYPELGMNAFSAVVCAPFLGSYRNPTLGIDDRWLENDGIVNT
VSMNGPKRGSSDRIVPYDGTLKKGVWNDMGTYNVDHLEIIGVDPNPSFDIRAFYLRLAEQLASLQP

Fig. 37

SEQ ID No. 26

DDYSVVEEHGQLSISNGELVNERGEQVQLKGMSSHGLQWYGQFVNYESMKWLRDDWGITVFRAAMYTSSG
GYIDDPSVKEKVKETVEAAIDLGIYVIIDWHILSDNDPNIYKEEAKDFFDEMSELYGDYPNVIYEIANEP
NGSDVTWDNQIKPYAEEVIPVIRDNDPNNIVIVGTGTWSQDVHHAADNQLADPNVMYAFHFYAGTHGQNL
RDQVDYALDQGAAIFVSEWGTSAATGDGGVFLDEAQVWIDFMDERNLSWANWSLTHKDESSAALMPGANP
TGGWTEAELSPSGTFVREKIRESASDNNDPIPDPDDEASLRANDAPIVLLHGFTGWGREEMFGFKYWGGV
RGDIEQWLNDNGYRTFTLAVGPLSSNWDRACEAYAQLVGGTVDYGAAHAAKHGHARFGRTYPGLLPELKR
GGRIHIIAHSQGGQTARMLVSLLENGSQEEREYAKAHNVSLSPLFEGGHHFVLSVTTIATPHDGTTLVNM
VDFTDRFFDLQKAVLEAAAVASNVPYTSQVYDFKLDQWGLRRQPGESFDHYFERLKRSPVWTSTDTARYD
LSVSGAEKLNQWVQASPNTYYLSFSTERTYRGALTGNHYPELGMNAFSAVVCAPFLGSYRNPTLGIDDRW
LENDGIVNTVSMNGPKRGSSDRIVPYDGTLKKGVWNDMGTYNVDHLEIIGVDPNPSFDIRAFYLRLAEQL
ASLQP

Fig. 38

SEQ ID No. 27

MKFVKRRIIALVTILMLSVTSLFALQPSAKAAEHNPVVMVHGIGGASFNFAGIKSYLVSQGWSRDKLYAV
DFWDKTGTNYNNGPVLSRFVQKVLDETGAKKVDIVAHSMGGANTLYYIKNLDGGNKVANVVTLGGANRLT
TGKALPGTDPNQKILYTSIYSSADMIVMNYLSRLDGARNVQIHGVGHIGLLYSSQVNSLIKEGLNGGGQN
TN

Fig. 39

SEQ ID No. 28

DDYSVVEEHGQLSISNGELVNERGEQVQLKGMSSHGLQWYGQFVNYESMKWLRDDWGITVFRAAM
YTSSGGYIDDPSVKEKVKETVEAAIDLGIYVIIDWHILSDNDPNIYKEEAKDFFDEMSELYGDYP
NVIYEIANEPNGSDVTWDNQIKPYAEEVIPVIRDNDPNNIVIVGTGTWSQDVHHAADNQLADPNV
MYAFHFYAGTHGQNLRDQVDYALDQGAAIFVSEWGTSAATGDGGVFLDEAQVWIDFMDERNLSWA
NWSLTHKDESSAALMPGANPTGGWTEAELSPSGTFVREKIRESASDNNDPIPDPDDEAEHNPVVM
VHGIGGASFNFAGIKSYLVSQGWSRDKLYAVDFWDKTGTNYNNGPVLSRFVQKVLDETGAKKVDI
VAHSMGGANTLYYIKNLDGGNKVANVVTLGGANRLTTGKALPGTDPNQKILYTSIYSSADMIVMN
YLSRLDGARNVQIHGVGHIGLLYSSQVNSLIKEGLNGGGQNTN

Fig. 40

SEQ ID No. 30

atgcatacgcgtgttaac

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2012/05166O

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K14/37 C11D3/38 C11D3/386 C12N9/20
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K C11D C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal , BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2009/101167 AI (BOECKH DIETER [DE] ET AL) 23 April 2009 (2009-04-23) cited in the application p. 2, paragraph [0028] - p. 9, paragraph [0150] -----	1-45
X	JOSÉ M. PALOMO ET AL: "Solid-Phase Handling of Hydrophobins: Immobilized Hydrophobins as a New Tool To Study Lipases", BIOMACROMOLECULES, vol. 4, no. 2, 1 March 2003 (2003-03-01), pages 204-210, XP55030962, ISSN: 1525-7797, DOI: 10.1021/bm0200711 the whole document -----	1,2,4, 16-19, 21-25, 31,32, 36-39

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) orwhich is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
29 June 2012	26/07/2012

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	R. von Eggelkraut-G.

1

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2012/051660

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 595 949 Al (TOHOKU TECHNO ARCH CO LTD [JP] ; NAT INST OF ADVANCED IND SCIEN [JP]) 16 November 2005 (2005-11-16) p. 6, paragraph [0030] - p. 10, paragraph [0084] , pp. 21-26, Ex. 4-9 -----	1, 16-32, 35,38,39
A	LINDER M B ET AL: "Hydrophobins: the protein-amphiphiles of filamentous fungi", FEMS MICROBIOLOGY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 5, 1 November 2005 (2005-11-01) , pages 877-896, XP027666169 , ISSN: 0168-6445 [retrieved on 2005-11-01] the whole document -----	1-45
A	HASAN F ET AL: "Enzymes used in detergents: Lipases", AFRICAN JOURNAL OF BIOTECHNOLOGY, ACADEMIC PRESS, US, vol. 9, no. 31, 2 August 2010 (2010-08-02) , pages 4836-4844, XP003027509, ISSN: 1684-5315 the whole document -----	1-45
A	MESSAOUDI ABDELMONAEM ET AL: "Classification of EC 3.1.1.3 bacterial true lipases using phylogenetic analysis", AFRICAN JOURNAL OF BIOTECHNOLOGY, vol. 9, no. 48, November 2010 (2010-11) , pages 8243-8247, XP002678951 , ISSN: 1684-5315 the whole document -----	1-45

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/IB2012/05166O

Patent document cited in search report		Publication date	Patent family member(s)			Publication date
US 2009101167	AI	23-04-2009	AT	485359	T	15--11--2010
			AU	2006274836	AI	08--02--2007
			BR	PIQ614703	A2	23--08--2011
			CA	2617092	AI	08--02--2007
			CN	101233220	A	30--07--2008
			EP	1913123	AI	23--04--2008
			ES	2352970	T3	24--02--2011
			JP	2009503280	A	29--01--2009
			KR	20080041228	A	09--05--2008
			US	2009101167	AI	23--04--2009
			WO	2007014897	AI	08--02--2007
			ZA	200801881	A	26--08--2009
EP 1595949	AI	16-11-2005	EP	1595949	AI	16--11--2005
			JP	4273504	B2	03--06--2009
			US	2006106120	AI	18--05--2006
			WO	2004038016	AI	06--05--2004